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Breast Cancer is the most commonly diagnosed cancer among women in New Zealand, with 
an estimated 3000 women diagnosed in New Zealand every year. The most common form of 
treatment is surgery, and following treatment, the approximate 5-year survival rate is 90%. A 
key part of the treatment process for breast cancer survivors is breast reconstruction surgery, 
as it improves the physical, physiological, and social aspects of every-day life. Autologous fat 
grafting is a relatively new breast reconstruction option that is becoming increasingly 
attractive, as this has the ability to create a natural cosmetic outcome with minimal surgical 
risk. The major limitation associated with fat grafting is that the percentage of grafted tissue 
volume that is retained post-surgery is hugely variable, prompting further breast 
reconstruction in some cases. Adipose derived stem cells (ADSCs) are a key cell being 
investigated in the donor tissue due to their high proliferative abilities, coupled with their 
potential to differentiate into adipocytes, indicating that they are important in the 
regeneration of adipose tissue. In the breast cavity, macrophages are thought to play an 
important role in graft retention as they are important in inflammation and wound healing. It 
is thought that improving the relationship between ADSCs in the donor tissue and stromal 
cells in the recipient site, such as macrophages, could be important for improving retention 
rates. One way in which these cells can interact is through the release of extracellular vesicles 
(EVs) from ADSCs into the surrounding environment.  
The overall aim of this study was to establish methodologies for in vitro ADSC and macrophage 
culture, for characterization of ADSC-derived EV (ADSC-EV) output during culture, and to 
determine the impact of ADSC-EVs on macrophage polarization. Adipose tissue samples were 
collected from patients undergoing fat grafting and ADSCs were isolated and cultured. ADSC 
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cell specificity was confirmed using flow cytometry as well as successful differentiation into 
adipocytes and osteoblasts, indicating the successful establishment of methods to culture 
ADSCs from autologous fat graft samples. 
ADSC-EVs were isolated from the media of cultured ADSCs using size exclusion 
chromatography and characterised using tunable resistive pulse sensing. We demonstrate a 
mean size 150 – 190 nm across patient samples, which is within the expected size range of 
EVs. Mean concentrations also ranged from 2.3x108 and 7.4x108 particles/mL as expected.  
Western blot analysis on proteins known to be present in EVs further confirmed presence of 
EVs in the collected samples. Together, these techniques indicated the successful isolation of 
EVs from cultured ADSCs. 
Monocytes were isolated from healthy volunteers, cultured into M0 macrophages and further 
polarized towards M1 and M2 macrophage phenotypes. Successful polarization into M0, M1-
like or M2-like macrophages was confirmed by assessing the morphology of cultures. Flow 
cytometry using known M1 and M2 markers, and RT-qPCR on pro- (TNFα, IL1-β) and anti-
inflammatory (IL-10, TGFβ) markers were also used to assess successful polarization. However, 
low cell counts made these methods difficult for assessing polarization and further 
optimization is required. 
In a further experiment, ADSC-EVs were added to M0, M1-like and M2-like macrophage 
cultures at the time of polarization. To analyse the impact of ADSC-EVs on polarization state, 
RT-qPCR was conducted to assess macrophage expression of pro- (TNFα, IL1-β) and anti-
inflammatory (IL-10, TGFβ) markers. The addition of ADSC-EVs to macrophage cultures altered 
the expression of pro- and anti-inflammatory markers in each of the polarization states, and 
could thus potentially influence polarization status of macrophages. The results of this study 
warrant further investigation to determine the role of ADSC-EVs on macrophage polarization. 
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However, the preliminary data here provides an exciting platform for future research into the 
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1.1 Breast Cancer – Prevalence and treatment 
1.1.1 Prevalence of Breast Cancer 
Breast cancer is the most commonly diagnosed cancer among women worldwide, making up 
a quarter of all cancer cases (1). It is estimated that 1.7 million women are diagnosed with 
breast cancer globally every year, with approximately 3000 being diagnosed in New Zealand 
alone (2, 3). In addition to this, Māori have one of the highest incidences of breast cancer, 
with a 28% higher incidence than NZ European women (4, 5). Due to the high rates of breast 
cancer, there have been significant advancements in treatments in recent decades, with a 
wide variety of options available. 
 
1.1.2 Treatment Options 
There are a number of different treatment options available for breast cancer, as outlined in 
Figure 1. These include local treatments, such as surgery and radiation therapy, as well as 
systemic treatments, such as chemotherapy and hormone therapy (6). The type of treatment 
received depends on the individual make-up of a patient’s breast cancer, which can include 
factors such as stage, grade, or molecular status (6, 7). Specialists in multidisciplinary teams 
will therefore determine treatment plans that are individualised based on each individuals’ 
cancer (6, 7). 
In the majority of cases, surgery is the mainstay of treatment for breast cancer (6). Depending 
on the size and location of the tumour, patients will undergo partial or full removal of one or 
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both breasts. A mastectomy involves the removal of the entire breast, whereas a lumpectomy 
is contained to the tumour and immediately surrounding tissue (6). Breast conserving 
surgeries, such as lumpectomies, are restricted to early stage patients, where the tumour is 
contained within a clear margin (8, 9). Advances in treatments have led to an approximate 5-
year survival rate of 90% following treatment (10). However, regardless of the type of surgery, 
there is likely to be significant deformation of the breast tissue, meaning that many of these 





Figure 1: Breast Cancer clinical treatment options in New Zealand. 
Clinical pathway for the general treatment options in New Zealand. Treatment plans are individualised for each 
patient following diagnosis. In New Zealand, patients can undergo one of more of the above treatments, with 
surgery being the most common (11). 
 
1.2 Breast Reconstruction 
1.2.1 Reconstruction 
Any patient undergoing a mastectomy in New Zealand is recommended to be referred for 
breast reconstruction surgery, and approximately half of the 3000 newly diagnosed New 
Breast Cancer Diagnosis 
following mammogram, 














-Bone specific therapy 
-Other targeted therapies 
SURGERY 
-Mastectomy 




Zealand women opt for this surgery per year (3, 12). Reconstruction is an important part of 
the treatment process as it helps to improve physical, physiological, and social aspects of 
everyday life for women affected by breast cancer (12, 13). It is therefore an integral part of 
the therapeutic process as it aims to improve the overall quality of life for these women (14). 
The aim of breast reconstruction surgery is to provide optimal shape, volume, and appearance 
of the breasts (15). There are currently a number of different breast reconstruction options, 
each with their own strengths and limitations (Table 1). The most common options include 
flap based reconstruction, implants, autologous fat grafting, or a combination of these 
techniques (2, 13). The type of reconstruction a patient receives depends on several factors. 
Firstly, the type of breast-removal surgery the patient has received can influence available 
reconstruction options. For example, if a small volume of tissue had to be removed during a 
lumpectomy, the goal of reconstruction would be to contour the impacted area in order to 
reform symmetry of the breasts (15). Implants would therefore not be an appropriate option 
for this form of reconstruction. Other factors influencing the type of reconstruction performed 
are clinical risk factors, patient comorbidities, and patient preference (8). 
 
1.2.2 Implant and Flap-Based Reconstruction 
Historically, implant-based and flap-based reconstruction have been the most common 
reconstruction techniques available. However, there is increasing interest in the relatively new 
technique of autologous fat grafting. Flap-based surgeries, which use muscle to reconstruct 
the breast, are preferred by many women as they tend to have a more natural appearance 
than reconstruction with implants (14). Unfortunately, flap-based techniques are technically 
demanding procedures and therefore come with a higher associated risk (13, 16). Additionally, 
patients can develop necrosis or shrinkage of the flap (13). They are not deemed a safe option 
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for patients with obesity, diabetes, or those who smoke (13). Obesity has been linked to 
significant increased levels of complications following flap-based reconstruction, including 
increased overall flap loss, hematoma and seroma, skin necrosis, donor site infection, and 
increased risk of surgical complications (17, 18). According to the New Zealand Health Survey 
of 2017/18, 32% of the New Zealand population are considered to be obese (19). Furthermore, 
Māori and Pacific Island women have increased levels of these comorbidities, with obesity 
rates being 47% and 65% respectively (19). The prevalence of obesity develops a level of 
inequity in access to certain breast reconstruction options between different populations in 
New Zealand (20). 
Implant-based reconstruction is a more straightforward surgery than flap-based and has a 
lower level of associated complications with the surgery itself (21). However, there are long-
term complications associated with implants. Firstly, there is a chance that the implant can 
rupture, or even migrate, and it is unlikely that a single surgery will suffice for the remainder 
of the patient’s life (21). The most common implant-associated complication is capsular 
contracture, where the immune system recognises the implant as foreign, and forms fibrous 
scar tissue around it (22). The development of a capsular contracture can cause the skin to 
shrink and lead to compression of the implant (22). As well as causing obvious deformities in 
the tissue, as well as pain, it is likely that patients will be required to receive another surgical 
intervention (23). There is also a small risk of developing implant-associated anaplastic 
lymphoma, a form of cancer arising from the implant itself. While the actual risk is only 0.3% 
per 100,000 women per year, this can cause a significant level of anxiety in individuals who 
have already had breast cancer (24). 
There are some obvious drawbacks with the current commonly used breast reconstruction 
options, and consequently, there is an apparent need for a safe and equitable option. In recent 
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years, there has been increasing interest in the relatively new technique of autologous fat 

























Flap-based • Possible to undertake 
immediately after 
mastectomy (17) 
• More natural in 
appearance than implants 
(14) 
• Technically demanding procedure 
(13, 16) 
• Difficult to undertake in patients 
with comorbidities (obesity, 
diabetes), or smokers (17) 
• Possible muscle damage or 
weakness (13) 
• Potential for some resorption (13) 
Implant • Possible to undertake 
immediately after 
mastectomy (33) 
• Short operation and 
recovery (21) 
• No donor site morbidity 
• Anxieties around the risks of 
developing implant-associated 
anaplastic lymphoma (24) 
• Likely to need to be replaced or 
removed later in life (21) 
• Implants can rupture (21) 
• Capsular Contracture (22) 
• Implant migration (21)  
Fat grafting • Natural cosmetic outcome 
(27) 
• Simple procedure 
compared to flap-based 
(lower associated risk) (27, 
28)  
• Fewer contraindications 
and therefore potentially 
more equitable (28) 
• Aids in post-radiation 
therapy pain (34) 





1.2.3 Autologous Fat Grafting 
Autologous fat grafting is the removal of liposuctioned fat from a donor site in the body, such 
as the hip or thigh, and the subsequent transfer to another area (25). Fat grafting is currently 
used worldwide for a number of different clinical and cosmetic procedures as a way to 
improve, contour, or enlarge desired areas (26). Fat grafting is associated with a lower 
associated surgery risk due to it being a comparatively simpler surgical procedure than current 
alternatives (27, 28). Additionally, there are no associated comorbidities that are known to 
reduce the efficacy of this procedure, therefore it is a potentially more equitable option (27, 
28). In recent years, it has become increasingly popular in the field of breast reconstruction 
due to the ability to produce a natural outcome with minimal associated risks (27). 
Initially, there were concerns that fat grafting may increase the risk of breast cancer 
recurrence (29). It was thought that the transfer of adipose tissue back into the breast cavity 
could promote tumour formation through the expression of protumorigenic factors, increased 
angiogenesis, or increased cell proliferation due to the presence of stem cells (29). However, 
there is currently no evidence that fat grafting increases the risk of recurrence. A recent clinical 
trial at the Nottingham Breast Institute compared tumour recurrence in 211 women who had 
received fat grafting to a control group of 422 women who did not receive reconstruction (30). 
The study concluded that there was no increased risk of recurrence between the two groups, 
indicating that fat grafting does not promote oncogenesis (30). 
While fat grafting has many desirable aspects, there are currently issues with the amount of 
the graft being retained. The percentage of fat graft retention post-surgery is unpredictable 
and varies widely, with reported retention rates ranging from 30-70% of the original graft 
volume (25). Therefore, in order to receive the desired results, patients must undergo multiple 
surgeries, which increases surgical complications and associated risks (31). Thus, it is currently 
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impractical to use fat grafting for full reconstruction. There is currently little information on 
what contributes to the poor retention rates, however, this is likely a combination of donor 
tissue and recipient site factors and their subsequent interaction (32). 
There are currently a number of investigations into ways to improve graft retention. 
Comparisons of different harvesting methods, such as cannula sizes and different liposuction 
pressures, have been made to determine the best method for the removal and subsequent 
survival of adipose tissue from the donor site (32). Different processing techniques have also 
been explored in order to minimise the transfer of contaminating debris, however there has 
been a lack of consensus as to which methods provide the best outcome (32). In particular, 
surgeons are also currently tailoring processing techniques in order to promote the 
incorporation of cells expected to improve graft survival, in particular Adipose Derived Stem 
Cells (ADSCs; 32). However, harvesting and processing techniques still vary across institutes, 
and a consistent and well-validated method has yet to be developed. 
 
1.3 Fat Graft Components 
1.3.1 Adipose Tissue 
Adipose tissue is recognised as an important endocrine organ as it releases signalling 
molecules that allows interaction with other organs (35). For example, Tumour Necrosis 
Factor-α (TNFα), Interleukin-6 (IL-6) and Transforming Growth Factor-β (TGFβ), are released 
from adipose tissue, which allows interaction with the immune system (35, 36). Adipose tissue 
contains a number of different cell types, with the most abundant being adipocytes (37). The 
heterogeneous stromal vascular fraction of adipose tissue contains the widest variety of cells, 
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including endothelial cells, ADSCs, and immune cells (36). One of the key cells being 
investigated for the success of graft retention are ADSCs.  
 
1.3.2 Adipose Derived Stem Cells 
ADSCs are a form of mesenchymal stem cell that are found in the stromal vascular fraction of 
adipose tissue (38, 39). They are typically characterised by cell surface markers and 
demonstration of pluripotent abilities. ADSCs have the ability to differentiate into a number 
of cell types, including adipocytes, osteoblasts, vascular endothelial cells, and chondrocytes 
(38). As they have the ability to regenerate, ADSCs have become a key area of investigation 
for the improvement of fat graft retention. ADSCs are thought to improve graft retention in a 
number of ways. Their high proliferative abilities, coupled with their potential to differentiate 
into adipocytes, indicates that they are important in the regeneration of adipose tissue (40). 
Additionally, as they have the ability to generate vessels that can aid in the survival of oxygen 
dependent adipose tissue (41). ADSCs could therefore play an important role in the success of 
the graft by minimising hypoxic necrosis while also promoting tissue regeneration (42).  
While it is still unknown why retention rates are so poor, it is thought that graft retention is 
reliant on the interaction between ADSCs in the graft with cells in the breast cavity (43). It is 
currently thought that the enrichment of ADSCs could improve graft retention through either 
promoting their retention within the breast cavity, or promoting their differentiation into 
adipocytes (44). However, there is currently no evidence as to if, or how, enrichment of these 
cells will improve graft retention. The first step in establishing both their research and 
therapeutic use is to develop a method to isolate and characterise ADSCs from fat grafts of 
women undergoing autologous fat grafting. 
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1.4 Extracellular Vesicles 
One way ADSCs can interact with the surrounding environment is through the secretion of 
small, membrane-bound packages called Extracellular Vesicles (EVs; 45). EVs are membrane-
bound packages that are released from cells into the extracellular space (46). They have 
important roles in intercellular communication and are integral in regulating the 
microenvironment (46, 47). EVs have been shown to be responsible for the transfer of 
information between cells, including proteins and nucleic acids. They carry the contents of 
their original cell, and can also be taken up by recipient cells (47). EVs are released by all 
human cells and are also able to travel in both the blood and lymphatic systems, further 
demonstrating their function in cell-cell communication (47).  
Studies have found that EVs released by ADSCs aid in a wide range of pro-regenerative 
functions in animals (45). They have the ability to stimulate signalling pathways involved in 
wound healing, such as ERK, Akt, and STAT3, as well as the expression of genes involved in 
growth and cell cycle progression (45). ADSC-EVs also play a role in proliferation and migration 
of endothelial cells, as well as promoting pro-angiogenic gene expression (45). ADSC-EVs 
therefore have the ability to promote tissue repair and angiogenesis, both of which are 
important factors in graft retention. In animal models, ADSC-EVs have been found to increase 
expression of anti-inflammatory mediators, which could play a crucial role in minimising the 
reabsorption of the fat graft via dampening of a directed immune response (45). All of this 
information provides some rationale to the possible pro-retention function of ADSC-EVs in 
animal models. However, little is known about whether this can be translated to human cells. 
The majority of the advantages for graft retention of ADSCs may therefore be due to their 




1.5 Recipient Site Components  
1.5.1 The Breast Cavity 
Normal breast tissue consists mostly of adipose tissue, which itself is made up of a number of 
different cell types, including immune cells (36). The make-up of the breast tissue of each 
individual who has had breast cancer and subsequent local therapies will be different (48). 
Firstly, a large proportion of the tissue is likely to have been removed during surgery. 
Additionally, the intervention of surgery or radiation therapy introduces a number of different 
cells to the site as both of these procedures induce inflammation (49). Radiation therapy is an 
effective way to kill cells in a targeted section of the breast post-surgery (50). These targeted 
procedures are known to cause necrosis in the area, and the leakage of intracellular content 
due to this necrosis can stimulate an immune reaction (49). This response, coupled with 
increased inflammation following surgical wound healing, means that the breast cavity post-
surgery and radiation therapy will have an increased presence of inflammatory cells (48). This 
increased presence of inflammatory cells in the breast cavity may play a role in the retention 
rates (51).  
 
1.5.2 Macrophages 
One type of inflammatory cell known to be present in the breast cavity at this time is 
macrophages (51). Macrophages play a key role in inflammation and the immune response. 
The inflammatory response in the body is tightly regulated, with multiple regulators for both 
maintaining and dampening inflammation (52). Macrophages are important in initiation, 
maintenance and resolution of inflammation in response to both pro- and anti-inflammatory 
cytokines (53). Macrophages are polarized towards having a more pro-inflammatory or more 
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anti-inflammatory phenotype, known as M1 and M2 respectively (52). While these are 
generally considered as two cell types, it has been proven that macrophage polarization is a 
continuum as opposed to distinct phenotypes, and that macrophages exist as a 
heterogeneous pool of phenotypes within humans (54, 55). It is the balance of these two 
polarization states that controls inflammation and maintains normal tissue function (53). 
M1-like macrophages are involved in the stimulation of the immune system (52). They are 
activated in response to pro-inflammatory cytokines, such as Interferon-γ (IFN-γ), in order to 
increase inflammation in response to bacterial infection or to initiate wound repair (52). 
Activated M1-like macrophages release pro-inflammatory cytokines, such as TNFα and 
Interleukin-1β (IL-1β), to increase inflammation and protect against infection (56). 
Uncontrolled activation of M1 macrophages can disrupt tissue homeostasis and cause damage 
to the host tissue, and therefore needs to be tightly regulated (55). 
M2-like macrophages are important for suppressing inflammation and mediating wound 
repair in response to anti-inflammatory cytokines such as Interleukin-4 (IL-4; 52). Activated 
M2-like macrophages release anti-inflammatory cytokines, such as IL-10 and TGFβ, in order to 
initiate tissue repair and remodelling (56). M2-like macrophages work to balance and regulate 
the inflammatory response of M1 macrophages in the body (57).  
 
1.5.2.1 Macrophages in the Breast Cavity 
Due to their role in inflammation and wound healing, macrophages are known to be present 
in the breast cavity after a mastectomy, and are therefore an important cell of interest for 
improving graft retention (57, 58). There is increasing interest in the roles of M1-like and M2-
like macrophages on graft retention rates. M2-like macrophages are known to have a role in 
tissue repair and dampening the inflammatory response, and may increase retention rates by 
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minimising the level of inflammation at the graft site (57). There is some evidence from in vivo 
studies that M2-like macrophages are an important cell in graft retention. M2 macrophage 
presence has been associated with increased angiogenesis, stem cell recruitment, and 
increased overall graft weight (57, 59). Stimulation and retention of M2-like macrophages 
within the breast cavity following mastectomy is therefore a hugely important area of 
research for improving fat graft retention rates (57). In order to investigate the importance of 
this cell type in fat graft retention, appropriate, well-documented and well-validated models 
of in vitro macrophage polarization need to be established. 
 
EVs secreted by ADSCs are one of the potential ways in which the graft can interact with the 
breast cavity as they provide a platform in which the two can interact with one another. One 
way of demonstrating this is by investigating the effect of ADSC-EVs on the polarization state 
of macrophages. More specifically, ADSC-EVs have the potential to promote an anti-
inflammatory microenvironment which can stimulate the polarization of M2-like 
macrophages and subsequently promote M2 macrophage-driven tissue repair.  
 
1.6 Aims and Objectives 
Fat grafting is a desirable form of breast reconstruction due to the provision of a natural 
cosmetic outcome with minimal associated risks. In order for this procedure to be a viable 
option for full breast reconstruction, retention rates of the grafted tissue need to be improved. 
It is evident that ADSCs from the donor tissue and M2-like macrophages in the recipient site 
both play an important role in fat graft retention. Therefore, developing our understanding of 
the relationship between these two sites and the cell types involved is a promising area of 
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future research. One mechanism of interaction of these cells is through the release of EVs 
from ADSCs. We will utilize a model whereby ADSC-EVs are applied to macrophages that could 
help to better understand the relationship between the two sites and the different 
polarization states of macrophages in the graft.  
 
The overall aim of this study was to determine the impact of ADSC-EVs on macrophage 
polarization (M1 or M2) and expression of pro- and anti-inflammatory markers. There were 
five main objectives. 
1 Isolate ADSCs from fat graft samples and confirm cell specificity by flow cytometry. 
2 Differentiate ADSCs into different cell types in order to demonstrate pluripotency. 
3 Isolate EVs from ADSCs and characterise by tuneable resistive pulse sensing. 
4 Isolate macrophages from healthy donors and polarize to M1- or M2-like phenotypes. 
5 Apply ADSC-EVs to macrophages and measure M1/M2 polarization using flow 
cytometry, as well as expression of pro- and anti-inflammatory markers using RT-qPCR. 
 
1.7 Hypothesis 
We hypothesised that the application of ADSC-EVs to macrophages would promote M2-like 
characteristics, indicating an overall anti-inflammatory response. This is because ADSC-EVs 
have been shown to have a role in mediating expression of anti-inflammatory markers and 
this could indicate improved tissue retention following fat grafting. Developing a better 
understanding of this relationship will allow us to manipulate it for better graft retention in 




A complete summary of the scientific experiments undertaken in this study are outlined in 
Figure 2. ADSCs were first isolated from patients and cell specificity was confirmed by flow 
cytometry and demonstration of pluripotent abilities. EVs were isolated from the culture 
media of ADSCs and were characterised by Tunable Resistive Pulse Sensing (TRPS) and 
Western blot. Macrophages were also isolated from healthy volunteers and polarized towards 
M1-like or M2-like. Polarization was assessed morphologically, as well as by flow cytometry 
and RT-qPCR. ADSC-EVs were also added at the time of polarization and ADSC-EV impact on 




Figure 2: Summary of all scientific experiments undertaken in this project. 
Numbers correspond to relative subsections in materials and methods section of this study. 
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Materials and Methods 
2.1 Ethical Considerations and Patient Cohort 
2.1.1 Ethical Approval and Recruitment of Patients undergoing Fat Grafting 
A total of eight patients were enrolled for this study. Patients were recruited if they had a 
history of breast cancer and were undergoing autologous fat grafting at Wellington Hospital. 
This study has ethical approval from the Health and Disabilities Ethics Committee (HDEC; 
19/CEN/23) and patients were consented by the researcher prior to their surgery. It was 
outlined that participation was voluntary, the participant was free to withdraw from the study 
at any time, and declining to participate would not impact overall treatment. Participants 
provided written, informed consent to collect adipose tissue samples during their surgery. 
Participants also provided consent for the researcher to collect prospective demographic and 
clinicopathologic information from hospital records. Each patient was assigned a unique study 
identification number, and information was stored de-identified in a password-protected 
web-based database on secure University of Otago servers, known as Research Electronic Data 
Capture (REDCap). 
 
2.1.2 Ethical Approval and Recruitment of Healthy Volunteers  
Self-reporting healthy volunteers (n=3) were recruited through poster advertisement. 
Participants provided written, informed consent to provide blood samples, as well as verbally 
reported demographic and medical information. All information was de-identified and stored 
on REDCap, with all information being linked to a unique study identification number. HDEC 
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approval for healthy volunteers was obtained for this study by the researcher (19/CEN/129; 
Appendix 1).  
 
2.1.3 Te Ara Tika 
It was paramount that this study, and the researcher, took into account ethical considerations 
surrounding Māori participation. The researcher undertook Tikanga Māori Research training 
through the Māori Research Advisory Group at Wellington Hospital. Additionally, the 
researcher carried out Ngai Tahu consultation for this study in accordance with University of 
Otago guidelines. The incorporation of Tikanga was of upmost importance in the study design. 
During the consenting process, participants were offered to have their tissue disposed of with 
an appropriate karakia (blessing), or using the standard disposal methods. Additionally, 
participants were asked to indicate whether they would like to be informed of the findings of 
the research. This aligns with the values of Te Whakahoki I te Taonga (return of the gift), as it 
allows the return of information, when requested, from their participation in the study. At all 
stages of the study, tissue samples were treated with a great deal of respect, and the values 
of Tikanga were consistently implemented and kept in mind. 
 
2.1.4 Patient Demographic and Clinicopathological Characteristics 
Patient demographics and clinicopathological characteristics were stored on the REDCap 
database. For patients undergoing fat grafting, demographic information was collected from 
hospital records and included; age, gender, ethnicity, and Body Mass Index (BMI). 
Clinicopathological information included; type of cancer, breast affected, stage, grade, 
molecular status, type of treatments undertaken for breast cancer, and whether they had 
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previous reconstruction surgeries. For healthy volunteers, information was obtained verbally 
from the participant and included; age, gender, ethnicity, ongoing medical conditions, and 
date of last illness. 
 
2.2 Adipose Derived Stem Cells 
2.2.1 ADSC Isolation 
Lipoaspirates were collected at Wellington Hospital at the time of surgery and ADSCs were 
isolated within an hour of surgical removal. ADSC isolation and culture had already been 
established in the lab. Following surgical collection, samples were transferred to a sterile 
facility, washed with Phosphate-Buffered Saline (PBS; Life Technologies) and digested using 
type IA collagenase (Sigma-Aldrich), diluted to 0.075% in PBS, for 40 minutes (mins). Fetal 
Bovine Serum (FBS; In Vitro Technologies) was depleted of EVs using ultracentrifugation at 
100 000 x g for 2 hours, before being added to stop the digestion. The sample was centrifuged 
at 1000 x g for 4 mins, the supernatant was removed, and the pellet was resuspended in ADSC 
cell culture media (Table 2). The centrifugation and resuspension in culture media were 
repeated, and cells were quantified using a haemocytometer, with 0.4% Trypan Blue (Sigma-
Aldrich) to determine viability. Cells were resuspended at 1x106 cells/mL in ADSC cell culture 
media, and 1 mL was added to 35 mm cell culture dishes. Cells were cultured at 37℃ with 5% 
Carbon Dioxide (CO2). Media was replaced on day one, and every three days subsequently. At 
80% confluence, cells were passaged by adding 0.25% Trypsin-EDTA (Sigma-Aldrich) and 
incubating at 37℃ until cells detached. Culture media was then added and the cells were 
centrifuged at 1500 x g for 4 mins. The supernatant was discarded and the cell pellet was 
resuspended in fresh culture media and plated. Cells were cultured until passage five. Media 
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was collected in passages two, three, and four, and stored at -80℃ following a pre-clearing 
spin at 2000 x g for 10 mins to remove debris. At passage five, cells were lysed using lysis 
buffer (miRVana mRNA Isolation Kit; Life Technologies), scraped from the dish, and the lysate 
was stored at -80℃. 
Table 2: Cell culture media stimulants for ADSCs 
Cell Type Culture Media 
ADSCs Dulbecco’s Modified Eagle Medium (DMEM; In Vitro Technologies) 
with 10% FBS, 1% penicillin-streptomycin (In Vitro Technologies). 
Adipocytes DMEM with 10% EV-depleted-FBS, 1% penicillin-streptomycin, 1 µM 
dexamethasone (In Vitro Technologies), 0.5 mM 
isobutylmethylxanthine (IBMX; In Vitro Technologies), 0.2 µM 
indomethacin (In Vitro Technologies), 10 µM insulin (Sigma-Aldrich) 
Osteoblasts DMEM with 10% EV-depleted-FBS, 1% penicillin-streptomycin, 0.1 µM 
dexamethasone, 50 µM ascorbate-2-phosphate (In Vitro Technologies), 
10 mM b-glycerolphosphate (Sigma-Aldrich) 
 
2.2.2 Characterisation of ADSCs via Flow Cytometry 
At passage three, cells from one flask were lifted from culture plates by adding 0.25% Trypsin-
EDTA and incubating at 37℃ until detached. ADSC culture media was then added and the cells 
were centrifuged at 1500 x g for 4 mins. The supernatant was removed and cell pellets were 
resuspended in PBS. ADSCs were then stained to determine their purity in culture based on a 
panel of markers, outlined in Table 3. All antibodies were sourced from Becton Dickinson. 
Antibodies were diluted in staining buffer (2% FBS, 0.1% Sodium Azide, 97.9% PBS) and 
samples were stained at 4℃ for 30 mins. Fluorescence minus one (FMO) controls were used 
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to delineate positivity. ADSCs were positively identified by their combined expression of 
CD166, CD105, and CD10. In addition, ADSCs were defined as CD31-negative and CD14-
negative, as these markers identify contaminating endothelial cells and monocytes, 
respectively. Peripheral Blood Mononuclear Cells (PBMCs) were used as a positive control for 
CD10 and CD31 staining. These had been previously isolated and stored at -80℃.  Cells were 
then fixed with 1% paraformaldehyde (PFA) at 4℃ for 20 mins, centrifuged at 400 x g for 12 
mins, and resuspended in staining buffer. Samples were analysed on a FACSCanto II cytometer 
(Becton Dickinson), and data was analysed using FlowJo software (version 10.6.1). Live, single 
ADSCs were identified as represented in the gating strategy in Figure 3.  
 
Table 3: Panel design for assessing ADSC characteristics 
Antibody 






Expected to be 
present on live 
ADSCs? 
CD166 (3A6) Mouse IgG1, κ Violet (AF405) 1:20 Yes 
CD105 (266) Mouse IgG1, κ Red (APC) 1:20 Yes 
CD10 (HI10a) Mouse IgG1, κ Blue (PE) 1:5 Yes 
CD31 (WM59) Mouse IgG1, κ Violet 
(AmCyan) 
1:20 No 
CD14 (MϕP9) Mouse IgG2b, κ Blue (PECy7) 1:20 No 






Figure 3: Gating strategy to identify live ADSC population. 
ADSCs were identified by their forward scatter (FSC-A) and side scatter (SSC-A) properties (A). Doublet exclusion 
was performed by examining the FSH-H vs. FSC-A profile (B) and, finally, live cells were gated on based on their 
negative expression of FVS780 (C). 
 
2.2.3 Differentiation of ADSCs 
To determine whether ADSCs were pluripotent, cells were differentiated into adipocytes and 
osteoblasts. ADSCs were seeded at 1x106 cells/mL and cultured at 37℃/5% CO2 in cell culture 
chamber slides (Sigma-Aldrich). ADSCs were plated in ADSC culture media overnight before 
washing in PBS and culturing in media with differentiation stimulants. Culture media for ADSC 
24 
 
differentiation into adipocytes and osteoblasts is outlined in Table 2. Media was changed 
every three days for three weeks and cells were fixed in 4% PFA at room temperature for 15 
mins. Adipocytes were stained with 0.5% Oil Red-O (Sigma-Aldrich) and osteoblasts were 
stained with 2% Alizarin Red (Sigma-Aldrich) for 15 mins at room temperature. Cells were then 
washed in PBS and air-dried before being visualised on an Olympus BX51 microscope and 
imaged using an Olympus DP20 camera. 
 
2.3 Extracellular Vesicles 
2.3.1 Isolation of ADSC-EVs 
Previously stored cell culture media from ADSC cultures was thawed at room temperature and 
centrifuged at 2000 x g for 5 mins to pellet any debris. EVs were isolated from the supernatant 
using Size Exclusion Chromatography (SEC) qEV10/70 nm columns and an automated fraction 
collector (Izon).  
Initially, five fractions were isolated per 10 mL sample following a 20 mL void volume, with 35 
mL of PBS was used as a buffer per sample. Fractions were concentrated down individually by 
centrifuging at 4000 x g for 2 mins using Amicon Ultra-15 Centrifugal Filter Units (Amicon). 
These individual fractions were analysed on the qNano Gold (Izon) to determine size and 
concentration of particles within each individual fraction.  
For each patient, EVs from 10 mL of passage two media were isolated by collecting the first 
four fractions after the 20 mL void (Izon). From each of the four 5 mL fractions, 1 mL was 
removed, pooled per patient, and concentrated to 300 µL using Amicon Ultra-15 Centrifugal 
Filter Units (Amicon) by centrifuging at 4000 x g for 2 mins. The concentrated product was 
stored at -80℃ to be used for size and count analysis on the qNano Gold (Izon). 
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The remainder of the isolated EV fractions were pooled per patient and ultracentrifuged at 
100 000 x g for 2 hours. The supernatant was removed, the pellet was resuspended in 100 µL 
of Exosome Resuspension Buffer (Invitrogen), and stored at -80℃ for protein quantification 
by a bicinchoninic acid (BCA) assay and analysis by Western blot. 
For the isolation of ADSC-EVs to be applied to macrophages, 45 mL of pre-stored cell culture 
media from passage three was used per ADSC patient, and EVs were isolated using qEV10/70 
nm columns (Izon). These were then further concentrated using Amicon Ultra-15 Centrifugal 
Filter Units (Amicon), as above, and applied fresh to macrophage cultures. 
 
2.3.2 Characterisation of EVs using TRPS 
Size and concentration of ADSC-EVs was analysed by TRPS using the qNano Gold (Izon). 
Standard protocols from the manufacturer were followed for the use of the qNano. All 
samples were run through an NP200 nanopore (Izon), applying a stretch ranging from 46.9-
47.1 mm. Voltages used were between 0.32 and 0.36 V, and currents were kept between 75-
125 nA. Samples were run until a particle count of at least 500 was reached. CPC200 
calibration beads (Izon) were diluted 1:200 in PBS and used to calibrate samples. Concentrated 
ADSC-EVs, isolated as in 2.4.1, were thawed at room temperature, centrifuged at 2000 x g for 
5 mins, and run undiluted to quantify concentration and size of particles present. Results were 
analysed using Izon Control Suite (version 3.3). This included concentration, size (mean and 
mode), as well as representative histograms (Appendix 3), rate plots and signal trace graphs. 





Figure 4:  EV Characterisation using TRPS 
A) Representative signal trace of current in nanoamps (nA) versus time in seconds (s) with current spikes as 
particles flow through the nanopore. B) Representative rate plot of particle count versus time (s) on EVs extracted 
from cell culture media from an ADSC sample. Sample was measured on an NP200 nanopore, with a voltage of 
0.32 V and a stretch of 46.99 mm. Particles were calibrated using CPCP200 calibration beads (1:200 dilution). 
 
2.3.3 BCA Assay 
Protein concentrations were quantified for previously isolated ADSC-EVs stored in lysis buffer. 
Protein was quantified using 25 µL of standard or sample, and the Pierce BCA Protein Assay 
Kit (Thermo Scientific), following the manufacturers protocol. Concentrations for samples 
were calculated using a standard curve. Standards were run in triplicate and samples were run 
in duplicate. Samples with sufficient protein were used for Western blot analysis. 
 
2.3.4 Western Blot 
Previously isolated ADSC-EVs stored in lysis buffer were thawed at room temperature. For 
every 28 µL of sample, 7 µL of Pierce Lane Marker Reducing Sample Buffer (Thermo Scientific) 
was added. Samples were heated at 95℃ for 5 mins before loading 35 µL per sample to 
subsequent wells of a Novex Wedgewell 4-20% Tris-Glycine Gel (Invitrogen). In a separate 
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well, 10 µL of iBright Prestained Protein ladder (Thermo Fisher Scientific) was used as the 
protein size marker. Samples were electrophoresed at 150 V for 60 mins using Tris-Glycine 
SDS Running Buffer (Novex) diluted 1:10 in distilled water (dH2O).  
Samples were transferred to a nitrocellulose membrane (Invitrogen) using Power Blotter 1-
Step Transfer Buffer (Invitrogen) diluted 1:10 in dH2O. Transfer was completed using a Power 
Blotter (Invitrogen) at 25 V and 1.3 A for 7 mins. The membrane was then washed three times 
in T-TBS, made up of Tris Buffered Saline (TBS; Thermo Scientific) diluted 1:20 in dH2O, with 
0.1% TWEEN 20 (Sigma). The membrane was incubated rocking at room temperature for 60 
mins in 5% Bovine Serum Albumin (BSA; In Vitro Technologies) in T-TBS (blocking solution). 
The membrane was then briefly washed in T-TBS before being incubated in the desired 
primary antibody (Table 4) at 4℃ overnight.  
The following day, the membrane was washed 3 x 5 mins in T-TBS prior to incubation in the 
secondary antibody, diluted 1:1000 in blocking solution, for 60 mins rocking at room 
temperature. The secondary antibody was a Goat Anti-Mouse HRP-conjugated antibody (R&D 
Systems), that detects mouse IgG1, IgG2A, IgG2B, and IgG3. The membrane was then developed 
using SuperSignal West Femto Maximum Sensitivity Substrate Kit (Thermo Scientific) diluted 
1:2 in dH2O. The membrane was developed in this solution in the dark for 5 mins before being 








Table 4: Primary antibodies for Western blot 
Antibody Target 
(clone) 
Isotype Dilution in blocking 
solution 
Company 
ALIX (3A9) Mouse IgG1, κ 1:1000 BioLegend 
CD9 (5G6) Mouse IgG1, κ 1:1000 Novus 
 
2.4 Macrophages 
2.4.1 Macrophage Isolation 
Whole blood (20 mL) was collected via venepuncture from three healthy volunteers using 
EDTA-anticoagulated tubes and incubated at room temperature for 10 mins. Monocytes were 
isolated by adding 0.05 mM of RosetteSep human enrichment cocktail (STEMCELL 
Technologies) and incubated at room temperature for 20 mins. Samples were then diluted 1:2 
in PBS and layered on top of density medium Ficoll-Paque PREMIUM (GE Healthcare). Samples 
were centrifuged at 1200 x g for 20 mins with a slow start and brakeless deceleration. The 
monocyte layer was isolated and added to cold PBS and centrifuged again at 100 x g for 20 
mins at 4℃, with a slow start and slow stop. The supernatant was removed, the cell pellet was 
resuspended in cold PBS, and centrifuged at 100 x g for 20 mins at 4℃, with a slow start and 
slow stop. The cell pellet was then resuspended in M0 culture media (Table 5), counted using 
the haemocytometer, and monocytes were resuspended in media at 1x106 cells/mL. 1 mL was 
added to each well of non-treated 6-well tissue culture plates and cultured at 37°C/5%CO2. 
Additionally, macrophages were plated onto chamber slides to assess morphological 
differences. Media was changed on day one to remove non-adherent cells, and every three 
subsequent days for seven days to promote growth of macrophage populations. 
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2.4.2 Macrophage Polarization 
Following isolation, macrophages were polarized to M1-like or M2-like in culture media 
outlined in Table 5, and polarization was assessed by morphology, flow cytometry, and RT-
qPCR. The polarization timeline and pathway is outlined in Figure 5. 
 
 
Figure 5: Timeline of polarization for each of the three analyses performed. 
Macrophages were cultured at M0 for one week before being cultured in cell culture media containing 
polarization stimulants. Cells were polarized for 48hrs for flow cytometry analysis and seven days for 
morphological analysis. RT-qPCR analysis was assessed following seven days of polarization, with ADSC-EVs 









Table 5: Culture media stimulants for M0, M1 and M2 polarization of macrophages 
Polarization Culture Media 
No polarization 
(M0) 
Roswell Park Memorial Institute (RPMI) supplemented with 10% EV-
depleted-FBS, 1% penicillin-streptomycin, and 100ng/mL Macrophage 
Colony Stimulating Factor (M-CSF). 
M1 RPMI supplemented with 10% EV-depleted-FBS, 1% penicillin-
streptomycin, 50 ng/mL Granulocyte Macrophage Colony Stimulating 
Factor (GM-CSF) (Sigma-Aldrich), and 20 ng/mL IFN-γ (Sigma-Aldrich) 
M2 RPMI supplemented with 10% EV-depleted-FBS, 1% penicillin-
streptomycin 50 ng/mL M-CSF and 10 ng/mL IL-4 (Sigma-Aldrich) 
 
2.4.3 Confirming Macrophage Polarization by Imaging 
On day 14, polarization media was removed and wells were washed with PBS. Cells were fixed 
using 4% PFA for 15 mins at room temperature, washed in PBS again, and air-dried before 
being visualised on an Olympus BX51 microscope and imaged using an Olympus DP20 camera. 
 
2.4.4 Confirming Macrophage Polarization by Flow Cytometry 
After 48 hours of polarization, macrophages were lifted from the plates by incubating in 
Acctuase (Sigma-Aldrich) for 20 mins at room temperature. Samples were centrifuged at 1500 
x g for 4 mins, the supernatant was removed, and cells were resuspended in PBS. Cells were 
plated and incubated in Fixable Viability Stain (FVS780; Becton Dickinson) diluted in PBS at 4℃ 
for 30 mins. Samples were centrifuged at 400 x g for 12 mins, the supernatant was removed, 
and cells were resuspended in FC blocking solution (Biolegend) diluted 1:40 in staining buffer. 
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Following a 10 min incubation at room temperature, samples were centrifuged at 400 x g for 
12 mins, and the supernatant was removed. Cell surface staining was completed by 
resuspending cells in an antibody cocktail, as outlined in Table 6, with the exception of CD68, 
for 30 mins at 4℃. All antibodies were sourced from Becton Dickinson. FMO controls were 
used to delineate positivity. Antibody dilutions were determined from an antibody titration 
experiment (Appendix 4). Cells were then fixed with 1% PFA at 4℃ for 20 mins, centrifuged at 
400 x g for 12 mins, and washed twice with permeabilisation buffer (Biolegend) diluted 1:10 
with dH2O. Intracellular staining of CD68 was completed by incubating cells in anti-CD68 for 
30 mins at 4℃. Samples were again centrifuged at 400 x g for 12 mins, and cells were 
resuspended in staining buffer. Samples were analysed on a FACSCanto II cytometer (Becton 
Dickinson), and data was analysed using FlowJo software (version 10.6.1). Live, single cell 
populations were identified as represented in the gating strategy in Figure 6.  
 
Table 6: Panel design for assessing M1 and M2-like characteristics of macrophages 
Antibody Target 
(clone) 




Dilution in final 
staining volume 
CD80 (L307.4) Mouse IgG1, κ M1 Violet (BV510) 1:20 
CD68 (Y1/82A) Mouse IgG2b, κ M1 Blue (FITC) 1:20 
CD86 (2331) Mouse IgG1, κ M1 Blue (BB700) 1:20 
CD163 (GHI/61) Mouse IgG1, κ M2 Violet (BV421) 1:20 
CD206 (19.2) Mouse IgG1, κ M2 Blue (PE) 1:5 
CD36 (CB38) Mouse IgM, κ M2 Red (APC) 1:5 





Figure 6: Gating strategy to identify live macrophage population. 
M0 macrophages were identified by their forward scatter (FSC-A) and side scatter (SSC-A) properties (A). Doublet 
exclusion was performed by examining the FSH-H vs. FSC-A profile (B) and, finally, live cells were gated on based 
on their negative expression of FVS780 (C). 
 
2.4.5 Assessing the Effect of ADSC-EV Co-culture on Macrophage Polarization by 
RT-qPCR 
On day eight, cultures were supplemented with polarizing agents and freshly isolated ADSC-
EVs as follows: 1) M0, 2) M1 polarization, 3) M2 polarization, 4) M0 with EVs, 5) M1 
polarization with EVs, 6) M2 polarization with EVs. Polarizing agents applied to cell culture 
media are outlined in Table 5. For each patient receiving fat grafting, ADSC-EVs were isolated 
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as outlined in 2.3.1 and 300 µL was applied directly to the desired wells. This process was 
repeated for each of the three healthy volunteers, such that ADSC-EVs from one patient was 
applied to macrophages from three healthy volunteers. Cultures without ADSC-EV treatments 
had an equal volume of PBS added to cell culture media as a vehicle treatment. The M1 and 
M2 polarized cultures were used as positive controls for assessing the type of polarization that 
occurs in monocyte-derived macrophages supplemented with ADSC-EVs in the absence of 
polarizing agents (M0). Macrophages from all culture conditions were harvested at day 14. 
Cells were lifted from the plate by incubating in Acctuase (Sigma-Aldrich) for 20 mins at room 
temperature. Macrophages from each of the six different culture conditions were pooled 
across the three healthy volunteers. Samples were centrifuged at 1500 x g for 4 mins, the 
supernatant was removed, and cells were resuspended in PBS to count on the Guava easyCyte 
8HT Flow Cytometer (Millipore). Samples were centrifuged at 1500 x g for 4 mins, the 
supernatant was removed, and cells were resuspended in lysis buffer (miRVana miRNA 
Isolation Kit; Life Technologies) and stored at -80℃ for quantitative reverse transcriptions 
polymerase chain reaction (RT-qPCR) analysis. 
Each of the six macrophage cultures were thawed at room temperature and total RNA was 
isolated using the miRVana Isolation Kit (Life Technologies) following the manufacturers 
protocol. Double-stranded cDNA was synthesised using 8 µL of RNA and the SuperScript IV 
VILO Master Mix with ezDNase Enzyme (Thermo Fisher Scientific), following the 
manufacturers protocol. Expression of TNFα, IL-10, IL-1β and TGFβ were measured by real-
time qPCR using TaqMan Fast Advanced Master Mix, TaqMan Probes (Applied Biosystems) 





2.5 Statistical Analysis 
mRNA was measured using cycle threshold cycle values (Ct). The threshold was set at 0.14526 
during the log phase of replication for each run, as outlined in Figure 7. Each sample was run 
in duplicate, with duplicate Ct values being less than 0.5 units apart. Ct values for housekeepers 
GAPDH and HPRT1 were averaged to obtain the geometric mean and used to normalise the 
TNFα, IL-10, IL-1β and TGFβ average Ct values. The relative expression to samples without EVs 
for each sample was calculated using the 2-ΔΔCt method (60). GraphPad Prism software 
(GraphPad Prism 8.0.2 software, Inc) was used for the generation of graphs. 
As this study only analysed macrophage polarization following the application of ADSC-EVs 
from a single patient, no statistical analysis was able to be performed. However, the mRNA 
values are displayed as the technical average of two duplicates. 
 
 
Figure 7: Representative RT-qPCR curves for samples performed in duplicates. 




3.1 Cohort Characteristics 
Adipose tissue samples were collected from women with a history of breast cancer who were 
undergoing autologous fat grafting at Wellington Hospital. A detailed outline of the 
demographic and clinicopathological characteristics of the patient cohort is outlined in Table 
7. The mean age of the cohort of analysed samples (n=5) at the time of surgery was 50 years 
(± 9), and the mean BMI was 22.7 (± 4). The cohort was predominantly NZ European (n=3), 
with one Māori, and one African patient. Additionally, all patients have had previous surgical 
removal of part of the breast as part of their breast cancer treatment. The majority (n=4) had 
a mastectomy, while one patient had a wide local excision, which preserves a larger portion 
of the breast. Two out of the five patients have had some form of previous reconstruction 
surgery prior to fat grafting. 
For the healthy donor cohort used for the isolation of macrophages, all patients were female, 
self-reporting healthy volunteers, and the mean age for this cohort was 28 years (± 5) at the 









Table 7: Demographic and clinicopathological characteristics for patients receiving fat grafting 
Characteristic  N (%) Mean ± SD 
Cases  5  
Age   50 ± 9 
BMI   22.7 ± 4 














Type of Tumour 
Resection 
Mastectomy 



















3.2 ADSC Isolation and Characterisation 
3.2.1 Tissue Collection and ADSC Isolation 
The mean weight of adipose tissue samples was 147 ± 67 mg. Following digestion, cells were 
counted and cell viability was assessed with Trypan Blue, with a mean cell yield of 7.13 x 105 
cells/mL. Adipose tissue weights, location, cell yields, and viability are all outlined in Table 8. 
37 
 
Table 8: Tissue weight, cell yield and viability of stromal fractions 
Patient Donor Tissue Location Donor Tissue Weight Cell Yield Viability 
AD5 Hip, abdomen 77 mg 2.50 x 105 cells/mL 51% 
AD7 Hip 114 mg 9.86 x 105 cells/mL 29% 
AD8 Thigh 175 mg 6.08 x 105 cells/mL 75% 
AD10 Hip 250 mg 1.12 x 105 cells/mL 80% 
AD12 Hip 120 mg 1.61 x 106 cells/mL 85% 
 
 
3.2.2 ADSC Specificity Confirmed by Flow Cytometry 
Flow cytometry analysis was used to confirm that the cells isolated and cultured from fat graft 
samples were ADSCs. The first two consecutive patient samples were analysed to confirm cell 
specificity. The antibody panel contained five antibodies, three of which were expected to be 
expressed on the surface of ADSCs (CD166, CD10, CD105), and two that were not (CD14 and 
CD31). Previously banked PBMCs were used as a positive control for surface expression of 
CD14 and CD31. PBMCs not highly expressing CD14 and CD31 were gated on, and the gates 
were transferred to the ADSC population. CD14 was found to be dimly expressed in the ADSC 
population (Figure 8A), but expressed on some monocytes within the PBMC population 
(Figure 8B). Similarly, CD31 was not expressed in the ADSC population (Figure 8C), but was 





Figure 8: ADSCs are negative for the expression of the monocyte marker, CD14, and the endothelial marker, 
CD31. 
ADSC populations were negative for the expression of CD14 and CD31 (A & C). PBMCs had positive expression of 
CD14 and CD31 (B & D). Representative plots from n=1 patient sample. 
 
Using the gating strategy shown in Figure 8, the ADSC population was then hierarchically gated 
on to exclude CD14-positive and CD31-positive cells. This population was taken to see if there 
was expression of positive ADSC markers CD105, CD10, and CD166. In the representative plot 
below (Figure 9B), 99.7% of the population expressed both of these markers compared to the 
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corresponding FMO controls (Figure 9A and C). Additionally, when CD166 was examined in 
place of CD10, 99.5% of the population were expressing both CD166 and CD105 (Figure 10B) 
compared to the corresponding FMO controls (Figure 10A and C). Representative plots from 
flow cytometry analysis on a subsequent patient are presented in Appendix 2. 
 
 
Figure 9: ADSCs are positive for the expression CD105 and CD10. 
A) CD105 FMO showed no positivity of CD105, but 99.8% expression of CD10 on the ADSC population. B) Full 
stain showing 99.7% of cells expressing both CD105 and CD10. C) CD10 FMO showed no positivity of CD10, but 




Figure 10: ADSCs are positive for the expression CD105 and CD166. 
A) CD105 FMO showed no positivity of CD105, but 99.8% expression of CD166 on the ADSC population. B) Full 
stain showing 99.5% of cells expressing both CD105 and CD166. C) CD10 FMO showed no positivity of CD166, but 
99.6% positivity of CD105. Representative plots from n=1 patient sample. 
 
3.2.3 ADSCs Differentiate into Adipocytes and Osteoblasts 
ADSCs were differentiated into adipocytes and osteoblasts in order to demonstrate 
pluripotency potential and further confirm cell typing. ADSCs in culture displayed typical 
morphology of triangular, stretched out bodies (61; Figure 11A). ADSCs that were 
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differentiated into adipocytes (Figure 11B) showed positive Oil-Red O staining, indicating the 
presence of lipid bodies. Cells had a typical rounded morphology, with obvious circular, lipid 
pockets that would be expected in adipocyte cultures (61). ADSCs that were differentiated 
into osteoblasts (Figure 11C) stained positive with Alizarin Red, indicating the presence of 
calcium deposits. Morphologically, these cells had larger, more rounded bodies when 
compared to ADSCs, as previously reported (61). 
 
 
Figure 11: ADSCs differentiate into adipocytes and osteoblasts. 
Cells were cultured for 3 weeks in differentiation media before being fixed in 4% PFA. A) Unstained ADSCs. B) 
ADSCs differentiated into adipocytes and stained with Oil Red-O. C) ADSCs differentiated into osteoblasts and 
stained with Alizarin Red. All cells from a single patient sample. Visualised at 20x on an Olympus BX51 microscope 




3.3 EV Production by ADSCs 
3.3.1 ADSC-EV Concentration and Size Analysed by TRPS   
Concentration and size of ADSC-EVs were measured using TRPS in order to confirm EV 
presence, and characterise particles. 
The concentration of EVs in each of the five fractions from the fraction collector were 
individually measured in order to ensure the most EV-abundant fractions were being 
collected. There was a normal distribution of particles in each of the five fractions, with the 
highest concentrations being in fractions two, three, and four (Figure 12A). The first four 
fractions were then pooled per patient sample, with the fifth fraction being excluded in order 
to ensure exclusion of protein aggregates and lipoproteins of a similar size, as per the 
manufacturers recommendation. 
Concentration and size were measured for each of the five patient samples. Particle 
concentrations against size demonstrated a normal distribution, as demonstrated in the 
representative histogram (Figure 12B). Histograms for all patient samples are displayed in 
Appendix 3. The concentration of particles measured ranged from 2.3x108 to 7.4x108 
particles/mL across the five patient samples (Figure 12C). The mean sizes of the particles 





Figure 12: EV characterisation by TRPS. 
A) Concentration of particles (particles/mL) in each of the five individual fractions collected by SEC columns from 
cell culture media from a single ADSC sample. B) Representative histogram of the concentration (particles/mL) 
versus particle diameter in nanometres (nm). C) Concentration (particles/mL) of particles in pooled fractions 1-4 
per patient sample. D) Mean size (nm) of particles in pooled fractions 1-4 per patient sample. Sample was 
measured on an NP200 nanopore, with a voltage of 0.32 V and a stretch of 46.99 mm. Particles were calibrated 
using CPCP200 calibration beads (1:200 dilution). 
 
3.3.2 Protein Concentrations Quantified by BCA Protein Assay 
A BCA protein assay determined the concentration of total protein in each of the five patient 
samples prior to completing a Western blot. Protein concentrations ranged from 2.38-375.28 
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µg/mL across the five samples, as outlined in Table 9. Samples with the highest protein 
concentration, AD7 and AD8, were selected for Western blot analysis. 
 
Table 9: Total protein concentrations in each patient sample 







3.3.3 Presence of ADSC-EVs Confirmed by Western Blot 
Aligning with the guidelines for the Minimal Information for Studies on EVs (MISEV; 62), 
Western blot analysis was performed in order to confirm that the isolated particles were EVs. 
Cytosolic protein ALIX, and transmembrane protein CD9, were targeted using antibodies 
outlined in 2.3.4. Protein content is outlined in Table 9, with only two samples having sufficient 
amounts for Western blot analysis. Total protein was loaded in order to detect presence or 
absence of the markers, with 4.4 µg. and 10.5 µg loaded for AD7 and AD8 respectively. 
 
Presence of ALIX was detected within the expected size range of 70-95 kilodalton (kDa), for 
both patient samples as can be seen from the bands present in Figure 13.  CD9 was also 
detected in both patient samples, indicating presence of this protein (Figure 13). Multiple 
bands were detected at 40, 55, 65, and 90 kDa, as outlined in the manufacturer’s manual. 
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While CD9 has a theoretical molecular weight of 25 kDa, it is commonly known to have 
multiple molecular weights due to post translational modifications, cleavages, and relative 
charges. 
 
Figure 13: ALIX and CD9 are detected in the isolated ADSC-EVs. 
Presence of proteins in lysed EVs isolated by SEC columns and ultracentrifugation. ALIX (1:1000 dilution) and CD9 
(1:1000 dilution) are both present in patient samples (AD7 and AD8). ALIX present at 70-95 kDa (kilodalton). CD9 
present at 40, 55, 65, and 90 kDa. 
 
3.4 Macrophage Polarization 
3.4.1 Polarized Macrophages Look Morphologically Different 
Macrophages were cultured at M0 for one week followed by polarization for one week before 
being fixed and imaged to assess morphological differences between the polarization states. 
As expected, macrophages polarized to M1, had a rounded appearance (Figure 14B), while 
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macrophages polarized to M2 appeared stretched and spindly (Figure 14C). M0 macrophages 
appear to have a mixture of these two morphologies (Figure 14A).   
 
Figure 14: M0, M1, and M2 polarized macrophages look morphologically different. 
Macrophages cultured at M0 for one week, and polarized for a further week before being fixed in 4% PFA. A) M0 
macrophages. B) M1 macrophages. C) M2 macrophages. Cell were visualised at 20x on an Olympus BX51 
microscope and imaged using an Olympus DP20 camera. Representative of n=1 sample. Size bar represents 200 
µm (micrometres). 
 
3.4.2 Polarized Macrophages Express Different Levels of M1 and M2 Markers via 
Flow Cytometry 
Macrophages were cultured at M0 for one week and cultured for a further 48 hrs with 
polarization media, before polarization states were analysed by flow cytometry. Putative M2 
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markers examined here included CD36, CD163 and CD206, and putative M1 markers included 
CD68, CD80 and CD86. Expression of these markers were compared on live macrophage 
populations that had been polarized to M0, M1 and M2. 
As outlined in Table 10, M0 and M2-like cells expressed almost all markers to varying degrees, 
while M1-like cells lacked expression of the majority of the markers.  
M0 macrophages expressed all of the M1 markers CD68 and CD86, except CD80 (Figure 15 A, 
D & G), as well as all of the M2 markers (Figure 16 A, D & G). 
M1 macrophages did not express M1 markers CD68 and CD80, however there was minimal 
expression of CD86 (Figure 15 B, E & H). M1 macrophages also minimally expressed M2 marker 
CD36, but did not express CD163 and CD206 (Figure 16 B, E & H). 
All three M2 markers were expressed to varying degrees in the M2 cultures (Figure 16 C, F & 
I), however, M2 cells also expressed the M1 markers (Figure 15 C, F & I).  
 
Table 10: Summary of the expression of putative M1 and M2 markers on M0, M1 and M2 polarized cells 
 Marker M0 M1 M2 
Putative M1  CD68 ++ - ++ 
Markers CD80 - - + 
 CD86 + + ++ 
Putative M2  CD36 + + +++ 
Markers CD163 +++ - + 
 CD206 + - +++ 




Figure 15: Putative M1 Markers. 
Macrophage polarization states were analysed by flow cytometry. Putative M1 markers included CD68, CD80, 
and CD86. CD68 was not expressed in M1 (B), but was expressed in M0 (A), and M2 (C) populations. CD80 was 
not expressed in M0 (D) or M1 (E), but was expressed in M2 (F). CD86 was expressed in M0 (G), M1 (H), and M2 




Figure 16: Putative M2 Markers. 
Macrophage polarization states were analysed by flow cytometry. Putative M2 markers included CD36, CD163, 
and CD206. CD36 was expressed in M0 (A), M1 (B), and M2 (C) populations. CD163 was not expressed in M1 (E), 
but was expressed in M0 (D) and M2 (F). CD206 was not expressed in M1 (H), but was expressed in M0 (G) and 
M2 (I). Macrophages isolated from n=1 healthy volunteer. 
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3.4.3 Polarized Macrophages Express Different Levels of mRNA Inflammatory 
Markers 
Macrophages were cultured at M0 for one week and cultured for a further week with 
polarization media, before polarization states were analysed by RT-qPCR. Macrophages from 
each of the three cultures were lysed and analysis was performed by RT-qPCR for pro- and 
anti-inflammatory markers to determine the levels of each of these markers in each of the 
polarization states. Patient samples were pooled immediately prior to lysis. Putative pro-
inflammatory markers used were TNFα and IL-1β, and putative anti-inflammatory markers 
used were IL-10 and TGFβ. Expression is displayed as relative to M0 macrophages. Pooled M1 
polarized macrophages showed 35-fold higher expression of TNFα compared to M0, while M2 
polarized macrophages had only slightly elevated expression (Figure 17A). IL-1β expression 
decreased in M1 cells compared to M0 cells, but was still higher expression than expression 
in M2 macrophages (Figure 17A). Expression of IL-10 was similar in all three states (Figure 








Figure 17: M0, M1 and M2 macrophages express different levels of inflammatory markers. 
Polarized macrophages were lysed and polarization states were assessed by RT-qPCR. A) Variable expression of 
pro-inflammatory markers TNFα and IL-1β were observed in M1 and M2 macrophages relative to M0. B) Variable 
expression of anti-inflammatory markers IL-10 and TGFβ was observed in M1 and M2 macrophages relative to 
M0. Macrophages were isolated from n=3 healthy volunteers and pooled. 
 
3.5 Macrophages Cultured with ADSC-EVs 
3.5.1 Macrophage Cell Counts Decrease Following Application of ADSC-EVs 
Cells were counted on the Guava easyCyte Flow Cytometer prior to being lysed for RT-qPCR 
analysis. This was to determine if addition of ADSC-EVs impacted overall cell count, as well as 
determining if there were differences in count between M0, M1 and M2 cells. 
M0 cells without EVs had a greater overall cell count of 1171 compared to M1 and M2, 
however M0 macrophages co-cultured with ADSC-EVs had a 91.2% lower count (Figure 18 A 
& B).  
M1 and M2 cells had a similar cell count without ADSC-EVs, with an absolute count of 483 and 
423 respectively (Figure 18 C & E). However, M1 and M2 cultures with EV treatment had 81.8% 




Figure 18: Macrophage cell counts decreased after addition of EVs. 
Macrophages were cultured at M0 for one week, before being polarized for a further week. ADSC-EVs or PBS 
(vehicle treatment) were added at the time of polarization. Cells were counter prior to RT-qPCR analysis. M0 cell 
counts are lower with the addition of ADSC-EVs (A & B). M1 cell counts were lower with the addition of ADSC-




3.5.2 ADSC-EVs Appear to Alter Expression of Pro- and Anti-Inflammatory Markers 
Following a week of culture with ADSC-EVs in polarization media, macrophages were lysed 
analysed using RT-qPCR to determine the levels of pro- and anti-inflammatory markers in each 
of the polarization states, both with and without EVs. 
Following treatment with EVs, relative expression of pro-inflammatory marker TNFα increased 
12-fold in M0 macrophages, however there was little change in expression in M1 and M2 
(Figure 19A). The greatest change in expression was in the other pro-inflammatory marker IL-
1β, with an 83- and 100-fold increase in M0 and M1 respectively, while in M2 there was a 455-
fold increase (Figure 19B) 
There was a 7-fold increase in the expression of anti-inflammatory marker IL-10 in M0 
macrophages following addition of ADSC-EVs (Figure 19C), however, there was little change 
in M1 and M2 macrophages. Expression of TGFβ decreased in both M1 and M2 macrophages 
after addition of ADSC-EVs, however, there was little change in M0 (Figure 19D). 
There were therefore variable changes in the expression of the markers across the polarization 





Figure 19: Expression of pro- and anti-inflammatory markers was different for macrophages treated with 
ADSC-EVs compared to untreated. 
Macrophages were cultured at M0 for one week, before being polarized for a further week. ADSC-EVs or PBS 
(vehicle treatment) were added at the time of polarization. Expression of pro- (TNFα, IL-1β ) and anti-
inflammatory (IL-10, TGFβ) were analysed by RT-qPCR. A) TNFα expression increased in M0 cells with EV 
treatment, but did not change for M1 and M2 cells. B) IL-1β expression increased in all three groups. C) IL-10 
expression increased in M0 cells with EV treatment, but did not change for M1 and M2 cells. D) TGFβ expression 
did not change for M0 cells, but decreased in M1 and M2 cells. Macrophages were isolated from n=3 healthy 





4.1 Key Findings 
This study has established methodologies for in vitro study of the interaction between ADSC-
derived EVs and macrophages. Using a cohort of patients receiving fat grafting, we successfully 
isolated and cultured ADSCs, as confirmed by flow cytometry and differentiation capabilities. 
ADSC-EVs were also successfully isolated from cell culture media during ADSC culture and 
characterised by TRPS. We established a methodology to isolate and polarize macrophages 
from healthy volunteers. Polarization was assessed morphologically, as well as through the 
expression putative M1 and M2 macrophage cell surface markers by flow cytometry, and the 
expression of inflammatory markers by RT-qPCR. Finally, we found that ADSC-EVs appear to 
impact expression of pro- and anti-inflammatory markers, however, we are limited in our 
ability to draw any conclusions regarding their pro- or anti-inflammatory properties at this 
stage. 
 
4.2 Patient Cohort 
Patients were recruited into this study if they were undergoing fat grafting at Wellington 
Hospital and had a history of breast cancer. No limitations were set on factors such as previous 
reconstruction, stage of cancer, previous radiation, BMI, ethnicity, or age. This was to ensure 
as many patients were recruited as possible for this initial pilot study. During the study 
timeframe, eight patients were recruited into the study, with only five able to be successfully 
characterised. Initially, a larger sample size of approximately 14 patients was expected to be 
achieved, however, this was restricted by factors beyond the researcher’s control. These 
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clinical factors limited the number of patients this study was able to recruit during the 
timeframe of this project. The most important of these factors was the re-scheduling of 
autologous fat grafting surgeries. Fat grafting is considered an elective surgery, and therefore 
is more likely to be cancelled or rescheduled in favour of more urgent surgeries. The surgeon 
at Wellington Hospital who completed all of the fat grafting procedures also performed breast 
cancer surgeries, such as mastectomies and lumpectomies. Therefore, there were a number 
of occasions when fat grafting procedures had to be rescheduled in order to accommodate 
these.  
Tissue samples were collected at the time of surgery and transferred from theatre directly to 
the laboratory to be processed within an hour of collection to ensure optimal cell viability. 
Weight and location of donor tissue was unable to be kept consistent as this was at the 
discretion of the surgeon. It should be noted, however, that donor tissue weight did not 
correlate to the cell yield of the stromal fraction that was obtained. Tissue weights were 
therefore likely to be more highly influenced by connective tissue, or abundant adipocytes, 
both of which were not of immediate interest to this study. Cells were seeded at 1 x 106 cells 
/ mL to minimise any disparities caused by different cell yields. 
Another factor that limited overall sample size was microbial contamination, a common 
obstacle in primary cell culture experiments (63). A total of eight patients were recruited into 
the study, however, three of these samples developed microbial contamination and the 
cohort size was therefore reduced to five patients. Bacteria and fungi are able to rapidly 
colonize cultures due to the optimal growing conditions already in place for cell culture (63). 
Primary cells in particular are prone to contamination as they originate from a heterogeneous 
tissue source that already contains a wide variety of cells and other possible contaminants 
(63). Initially, cell cultures were stored in an incubator alongside primary colorectal cancer 
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cells for another study. These cells are highly prone to microbial contamination, and two ADSC 
cultures were infected (64). Additionally, adipose tissue is more susceptible to fungal 
contamination than other tissue, and one sample was contaminated by a fungal infection (65). 
These samples were contaminated early on (in passage 0 or 1), therefore a sufficient level of 
cell culture supernatant was not able to be collected for adequate EV isolations, and these 
patients had to be removed from this study. Following this contamination, all subsequent 
ADSC collections were cultured in a separate incubator in order to prevent contamination. 
This study consequently had a total sample size of five ADSC patient samples. While this was 
less than initially intended, it was sufficient to optimise laboratory techniques for further, 
larger studies. 
Donor tissue location was also at the discretion of the surgeon, with three donor tissue 
samples isolated from the hip, one from the hip and abdomen, and one from the thigh. These 
are common donor sites for fat grafting due to their availability of subcutaneous adipose 
tissue, and therefore assessing the effects of ADSC-EVs from more than one donor site is 
clinically relevant (66). Donor tissue site is also largely influenced by the availability of adipose 
tissue. In some women, there is a scarcity of adipose tissue, therefore, donor tissue has to be 
taken from where it is available (66). As all samples were subcutaneous fat, not visceral, 
characteristics were largely preserved across donor sites. There is also no reported evidence 
of a relationship between donor site location and increased cell survival or function, and this 




4.3 Cultured Cells were ADSCs 
ADSCs are a form of mesenchymal stem cell that are found in the stromal vascular fraction of 
adipose tissue (38, 39). They are of particular interest in fat grafting as they have proliferative 
capabilities, as well as pluripotent capabilities (38). Currently, clinicians are enriching ADSCs 
prior to injecting them into the breast cavity, based on the assumption that their regenerative 
properties will aid in overall graft retention (68). However, there is currently little evidence 
into how, or even if, this is beneficial. The first step in establishing the potential use of ADSCs 
for future therapeutic use is to develop a method to isolate and characterise ADSCs. This study 
has demonstrated that it is possible to culture viable ADSCs from women undergoing 
autologous fat grafting, and provides a platform for future studies investigating the 
therapeutic potential of this cell type for improving overall graft retention. 
 
4.3.1 Cell Specificity was Confirmed by Flow Cytometry 
The first objective of this study was to confirm ADSC cell specificity at passage three using flow 
cytometry. The results show that the majority of the cultured population expressed our three 
chosen ADSC markers, CD10, CD105, and CD166, and did not highly express the two negative 
markers CD14 and CD31. Flow cytometry analysis confirmed that the vast majority of the cells 
cultured at passage three were ADSCs. 
 
4.3.1.1 Suitability of the Panel 
The flow cytometry panel was designed from well-established positive and negative ADSC 
markers in the literature. CD14 and CD31 are both known markers of haematopoiesis and are 
expressed on cells with haematopoietic capabilities (69, 70). Due to this, they are not highly 
59 
 
expressed on ADSCs and have commonly been used as negative markers for the detection of 
ADSCs (71-73). Monocytes within a heterogeneous PBMC population express both of these 
markers, therefore, PBMCs were selected as a positive control for the expression of these 
markers (69, 70).  
Markers used to positively identify ADSCs were CD10, CD105, and CD166. CD10 was selected 
as it is highly expressed on cells with adipogenic capabilities, such as ADSCs (71). CD10 is a cell 
surface enzyme that is frequently used in ADSC flow cytometry analysis as it has been reported 
to be highly expressed on ADSCs (71). CD105 was selected as it is a well-recognised marker of 
stem cells, and has been proven to be highly expressed on ADSCs (71, 74, 75). Lastly, CD166 
was chosen as a positive marker as it is expressed on cells that undergo extensive proliferation 
and differentiation, such as stem cells, as it is an important molecule involved in cell adhesion 
(76). All three of these markers have been used to positively identify ADSCs in a number of 
studies (71, 74-76). 
The combination of these five markers allowed for the design of a flow cytometry panel that 
is specific to, and characteristic of, ADSCs. There are a number of other markers that are 
known to aid in the characterisation of ADSCs. In particular, CD34 is a well-established marker 
for ADSCs in mouse models, however, this marker was excluded as expression of CD34 on 
human ADSCs has been reported to decline over time during cell culture (77). Other possible 
markers include CD90, CD44, and CD13, all of which have been proven to be promising 
markers for ADSC confirmation (78). While the panel used in this study was deemed to be 
sufficient to characterise the cultured cells as ADSCs, the inclusion of additional markers could 
have allowed for the potential identification of subpopulations. In future studies, a larger 
panel could be beneficial if identification of, and disparities between, these potential 
subpopulations was to be explored. This study focussed on developing a model to identify the 
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cultured cells as an ADSC population as a whole, and the flow cytometry panel used here was 
suitable for this purpose. 
 
4.3.2 Cultured Cells Demonstrate Pluripotency 
In order to further confirm that cultured cells were ADSCs, their ability to differentiate into 
different cell types was analysed. A key characteristic of stem cells is the ability to differentiate 
into a number of different cell types (79). There is some contention in the literature as to 
whether ADSCs are true stem cells, however, it is widely accepted that they should 
differentiate into adipocytes, osteoblasts, and chondrocytes (79). It is therefore standard 
practice in studies examining ADSCs to demonstrate pluripotent ability by differentiating them 
into at least two different cell types. While ADSCs are known to have the potential to 
differentiate into a number of cell types, the development of adipocytes, osteoblasts, and 
chondrocytes are most commonly used to demonstrate pluripotency (79). For this preliminary 
study, differentiation into two cell types was deemed sufficient to demonstrate pluripotent 
potential of these cells, with adipocytes and osteoblasts being chosen for their relative ease 
in time and labour over chondrocytes. 
Protocols for differentiation into these two cell types are relatively well established and 
consistent in the field, and therefore were adopted in this study (79, 80). Here, 
dexamethasone was used to initiate differentiation into both adipocytes and osteoblasts, as 
it is an important regulator of proliferation and differentiation (81). To further promote 
adipocyte differentiation, indomethacin, insulin, and IBMX were used. In combination, these 
stimulants promote adipogenesis by regulating the PPARg pathway, a key regulatory pathway 
in the development of adipocytes (82). To promote osteoblast differentiation, ascorbate-2-
phosphate was used as this increases cellular collagen secretion and stimulates the 
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phosphorylation of ERK1/2 in the MAPK pathway, which leads to increased gene expression 
of osteogenic proteins (83). Additionally, b-glycerolphosphate was used to provide phosphate, 
which is required to activate ERK1/2 (83). The use of these stimulants to activate these 
pathways to promote differentiation are therefore well established. 
Using these methods, we demonstrated clear morphological differences between ADSCs, 
adipocytes and osteoblasts. ADSCs demonstrated typical elongated, spindly morphology, with 
triangular bodies, while adipocytes demonstrated a rounded cell body, with obvious vacuoles 
(61). We confirmed the presence of lipid bodies due to positive red staining following the 
application of Oil Red-O in adipocytes. Lipid bodies are a characteristic of adipocytes, and are 
consistently used to confirm this cell type, as adipocytes are an important store of lipids for 
energy (84). Osteoblasts also demonstrated morphological differences to ADSCs, exhibiting a 
large, spherical body and nucleus. Development of calcium deposits within the cells was also 
detected by Alizarin Red. One of the key minerals stored by osteoblasts is calcium and 
therefore the presence of these deposits indicates successful differentiation (61). 
In future, differentiation of ADSCs to chondrocytes could be completed to further 
demonstrate differentiation potential. Additionally, to further confirm successful 
differentiation, studies could incorporate flow cytometry analysis of known adipocyte or 
osteoblast markers. The incorporation of these methods would further confirm that the 
morphological changes observed are representative of successful differentiation. For this 
study, the imaging and staining displayed was deemed sufficient to confirm successful 





We conclude that the majority of the cells being cultured are ADSCs. We demonstrated that 
99.7% of the population that are negative for both CD14 and CD31 and also positive for CD10 
and CD105. Additionally, 99.5% of the population are also positive for both CD105 and CD166. 
The morphological changes, as well as the positive red staining for Oil Red-O and Alizarin Red 
following differentiation, demonstrate that the cultured cells have the ability to differentiate 
into adipocytes and osteoblasts. The differentiation, coupled with the flow cytometry analysis, 
confirms that the majority of the population being cultured are ADSCs. 
We demonstrated that it is possible to culture viable ADSCs from women undergoing 
autologous fat grafting. Additionally, we have established methods in our laboratory for 
confirming that these isolated human cells are ADSCs. Due to their regenerative and 
pluripotent capabilities, ADSCs have the potential to play an important role in graft retention. 
We have developed a method to successfully culture and characterise these cells, and this is 
a first important step towards investigating their use as a therapeutic agent. 
 
4.4 ADSC-EV Isolation and Characterisation 
EVs are increasingly investigated as potential therapeutic agents as they have the ability to 
facilitate intercellular signalling (85). EVs are heterogeneous membrane-bound packages 
released from all cells that carry contents, such as nucleic acids and proteins, from their 
original cell (62). They have been associated with inflammation, tissue regeneration, 
differentiation, and even apoptosis, depending on the contents of the vesicle, which reflects 
the donor cell (86). EVs have therefore been recognised as a unique therapeutic option in 
recent years, leading to an escalation in the amount of EV-based studies taking place. 
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As they are highly heterogeneous, EVs can vary largely in size depending on their contents. 
EVs are broadly classed into three groups; exosomes (30 - 100 nm), microvesicles (100 nm -  1 
µm), and apoptotic bodies (1 – 5 µm; 62). This study focussed on total EVs to determine the 
role of this broad class of vesicles released by ADSCs and the potential roles they have on 
inflammation. In future, it would be beneficial to isolate and characterise each of these EV 
sub-types in order to determine the specific impact of each group. 
 
4.4.1 MISEV Guidelines 
Due to the increased interest in EVs as potential therapeutic agents, the International Society 
for Extracellular Vesicles developed the MISEV guidelines, which outlines recommendations 
for all studies involving EVs (62). These guidelines were developed with the intention of 
improving both the reliability and the reproducibility of EV-based studies. EVs have been 
notoriously difficult to characterise as they are a highly heterogeneous population (62). These 
guidelines outline the minimum requirements for isolation and characterisation of these 
particles in an attempt to develop a consensus amongst the literature. Since the introduction 
of these guidelines in 2014, studies involving EVs have evolved to become increasingly more 
detailed and homogenous when describing EV isolation and characterisation methods. While 
the MISEV guidelines have aided in minimising the lack of consistency across literature in an 
attempt to improve the techniques involved in EV studies, there are still a number of 
challenges associated with EV studies, which will later be outlined in 4.4.5. However, as the 
interest in EVs increases, there are an increasing number of techniques available for both the 
isolation and characterisation of these nanoparticles. The guidelines outline these options, 
illustrating the advantages and disadvantages of all techniques, as well as providing details 
around which techniques should be used in conjunction with one another in order to provide 
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the most transparent results. It is therefore important for us to extensively characterise the 
particles isolated in order to confirm that the isolated particles are EVs. Therefore, this study 
was in accordance with these guidelines and consistently ensured to use the most 
recommended, yet relevant, methods of both isolation and characterisation. The use of these 
guideline recommended techniques are discussed in the below paragraphs. 
 
4.4.2 EV Isolation 
In accordance with the MISEV guidelines, EVs released by ADSCs were isolated from cell 
culture media using SEC columns and an automated fraction collector. There are currently a 
number of methods for the isolation of EVs from samples, including precipitation, differential 
ultracentrifugation, density gradients, and SEC columns. 
One method of EV isolation is through precipitation targeting membrane particles in EVs. This 
method, while fast, is known to lack purity (87). There are frequently issues with the co-
precipitation of plasma lipoproteins, such as albumin and high density lipoproteins, as well as 
the co-precipitation of non-vesicular miRNA (87). As this study is aimed at aiding in the 
development of techniques that could potentially be transferred to a clinical setting, 
minimising the isolation of non-EV particles is an important factor to consider. This technique 
was therefore unlikely to be provide a pure enough isolation of EVs, and was therefore not 
used in this study. 
EV isolation using differential ultracentrifugation involves a series of centrifugal spins in order 
to remove cells and unwanted debris, followed by the final pelleting of EVs (88). This method 
can be time consuming, labour intensive, and continued exposure to centrifugal force can lead 
to deformities in the vesicles (88). Additionally, this method can result in the loss of a 
significant amount of EVs, decreasing the overall yield (88). Due to the similarities in the size 
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of both EVs and other possible contaminants, this method is known to isolate a mixture of 
vesicles and unwanted particles (88). For these reasons, this method was also not considered 
for this study. 
Two commonly used techniques for EV isolation recommended by the MISEV guidelines are 
SEC columns and density gradient ultracentrifugation. Density gradient ultracentrifugation 
involves the separation of particles in a sample based on their density (89). It requires a series 
of centrifugation steps in order to separate samples through a graded density medium (89). 
This technique has been reported to produce the most-pure EV populations, however it is 
heavily time consuming and laborious (89). 
SEC columns, such as the ones used in this study, separate particles based on size as they flow 
through the column. They are able to provide relatively pure isolates, however, they can still 
have some contamination from lipoproteins and are therefore not as pure as density gradient 
ultracentrifugation (89). SEC columns are able to isolate particles in a relatively short time 
frame, making them appealing for large-scale isolations. The introduction of automated 
fraction collectors in recent years has also increased the efficiency of SEC columns, minimising 
both the time and labour required for isolation. In this study, SEC columns were chosen as 
they have the greatest potential to be able to be transferred to a clinical setting, where EVs 
would need to be able to be isolated in a short time frame. While density gradient 
ultracentrifugation may provide purer isolates, this method is not feasible to use in clinical 
workflow due to the time constraints, and therefore was not used. 
 
4.4.3 EV Characterisation using TRPS 
Isolated EVs were characterised using TRPS on the qNano Gold, which is the current gold 
standard method for EV characterisation. Due to being highly heterogeneous particles, it was 
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important to characterise the size and count of EVs in the samples, as these are known to vary 
both within and between samples. According to the MISEV guidelines, TRPS provides the most 
accurate characterisation of vesicles. TRPS is considered the gold-standard technique, as it 
provides accurate size measurements of individual particles as they pass through a size-
specific nanopore and disrupt the electrical current running across it, while simultaneously 
measuring the concentration of particles within the sample (90). Measurements are calibrated 
to specific calibration beads of a known size and concentration, allowing for accurate 
measurements. TRPS is therefore able to accurately characterise both the size and count of 
individual particles in samples (90). 
Aside from TRPS, there are two common forms of EV characterisation; Electron Microscopy 
(EM) and Nanoparticle Tracking Analysis (NTA). EM can visualise EVs and distinguish them 
from other particles, however it is not a practical technique for counting EVs (91). 
Alternatively, NTA uses a laser to detect light scatter of particles suspended in liquid (92). This 
method is unable to measure particles individually, and therefore provides a bulk estimate 
with low accuracy and precision (92). TRPS was therefore deemed the most accurate 
technique for characterisation of EVs and was thus used in this study. 
The precision and accuracy of TRPS makes it desirable, however, it is technically challenging. 
Extensive training is required in order to overcome some of the technical issues of the system. 
It can be difficult to establish a stable current across the nanopore, which can be influenced 
by interference and background noise of the machine or the surroundings (93). There can also 
be challenges successfully opening the nanopore, or removing potential blockages caused by 
larger particles (93). However, due to the increasing interest in the potential therapeutic roles 




Analysis using TRPS requires the selection of a specific sized nanopore (93). There are a range 
of nanopore options measuring from 40 nm to as large as 11 µm. Conversely, NTA can only 
measure particles from 100 – 1000 nm (92). This study used an NP200 nanopore, which 
measures particles within the size range of 85 – 500 nm. Due to the size selection of the 
nanopore, the majority of the EVs measured are likely to be microvesicles, and any EVs smaller 
than 85 nm were therefore likely missed and unable to be characterised. Had a smaller 
nanopore been used, it is likely that we would have detected smaller EVs, such as exosomes. 
However, using a smaller nanopore would also have caused a loss of detection of particles at 
the larger end of the scale. For example, had an NP100 nanopore been used, we would have 
been able to detect particles as small as 50 nm, however, we would have lost detection of 
particles over 330 nm. Additionally, nanopores are prone to clogging by larger particles, with 
smaller nanopores having an increased risk of clogging. As our samples contained a wide range 
of particle sizes due to the collection of total EVs, an NP100 nanopore would have been 
particularly prone to clogging with the presence of these larger particles. The use of an NP200 
nanopore provided the widest range of detectable sizes and was used to characterise as many 
of the vesicles as possible. It should therefore be noted that these results are representative 
of the population of particles within the samples that fit within the size range of this nanopore. 
The MISEV guidelines also recommend that studies incorporate visualisation of EVs using EM 
to assess for spherical morphology of EVs. It is now possible to visualise and image EVs of 40-
300 nm using EM, allowing for further characterisation (91). While EM was not used for this 
study in particular, EVs isolated using SEC columns have previously been characterised by EM 




4.4.3.1 Patient Samples 
ADSC-EVs from the five patient samples were characterised using SEC columns and an 
automated fraction collector. The automated fraction collector separates particles that pass 
through the SEC columns based on size. When using a 10 mL cell culture media sample, 
particles are separated into 5 mL fractions following a void volume of 20 mL, using 35 mL of 
PBS as a buffer. In order to confirm collection of the most EV-abundant fractions, the first five 
fractions after the void volume were characterised individually. qNano analysis demonstrated 
that there were particles present in all five fractions, with the highest concentrations in 
fractions two, three, and four. As SEC columns separate particles based on size, it needs to be 
noted that these particles are not necessarily purely EVs, and could also be lipoproteins or 
other contaminating particles of a similar size. For this reason, when pooling patient samples 
for characterisation, the first four fractions were pooled and fraction five was excluded. This 
is because, according to the manufacturers protocol, fraction five is where protein levels start 
to increase and outweigh that of EVs due to their similarities in size (Izon). Numerous studies 
have been conducted by the manufacturer assessing EV and protein levels in each of the 
fractions, leading to the recommendation of the exclusion of fraction five in EV studies. 
Following this characterisation, all patient samples were pooled and quantified using the 
qNano Gold. EV release is known to vary between cell types, and there is little research into 
the isolation of EVs from cell culture media. However, the concentrations of particles 
measured in each of the five patient samples in this study are within the expected range for 
the basal release of EVs into cell culture media (94). The mean sizes, which ranged from 155 
nm to 190 nm, are consistent for the size range for both extracellular vesicles, and the chosen 




4.4.4 EV Presence Confirmed by Western Blot 
The MISEV guidelines recommend that any experiment involving EV confirms the EV presence 
through Western Blot analysis. For this study, Western blot was performed on isolated patient 
samples to further confirm that the particles being isolated were EVs. Furthermore, according 
to the MSIEV guidelines, to confirm the presence of EVs at least one cytosolic protein and one 
transmembrane protein must be used (62). ALIX (cytosolic protein) and CD9 (transmembrane 
protein) were used in this study to comply with these guidelines. ALIX is involved in membrane 
trafficking, miRNA packaging, and EV biogenesis, and is commonly used to confirm the 
presence of EVs (95). CD9 is transmembrane glycoprotein involved in cell adhesion and 
migration, and is known to be highly expressed on EVs (96).  
For this study, protein concentrations were quantified using a BCA assay, and Western blot 
analysis was performed on the two samples with the highest protein concentration. 
Interestingly, protein and EV concentrations did not correlate. As stated earlier, EVs are highly 
heterogeneous and carry a selection of proteins from their donor cell (47). This lack in 
correlation is likely due to a variation in the contents of the vesicles themselves, indicating 
that some EVs will carry greater amounts of protein than others.  
ALIX and CD9 were both present in the patient samples at the expected size. ALIX is visualised 
at 70-95 kDa, which is the expected molecular weight for this protein (97). According to the 
literature, CD9 is known to vary widely and the weight can change depending on post 
translational modifications, cleavages, and relative charges of the protein. Therefore, multiple 
bands are present at approximately 40, 55, 65, and 90 kDa (98). This presence of both of these 




4.4.5 Challenges with EV Studies 
There are a number of challenges that must be addressed with studies involving EVs. The first 
of these is the use of FBS in cell culture media. FBS is necessary to promote cell growth and 
survival, however, it also contains non-human EVs that are unable to be distinguished from 
ADSC-EVs during isolation (99). FBS-EV contamination is an issue for a number of reasons. 
Firstly, when collecting and characterising EVs from cell culture media, there is no way to 
distinguish between those originating from ADSCs, and those from the FBS. Additionally, as 
EVs are a form of cell-cell communication, FBS-EVs have the potential to be taken up by the 
ADSCs in culture, which can have an impact on the cells themselves (99). Not only are these 
EVs not from ADSCs, they are also not from human cells and therefore could impact the overall 
structure, signalling, or characteristics of the cultured ADSCs (99). In order to minimise the 
introduction of EVs originating from the FBS, all FBS was ultracentrifuged prior to use. 
Ultracentrifugation at 100 000 x g is known to pellet EVs, and therefore collection of the FBS 
supernatant allowed for the formation of EV-depleted FBS (100). However, it is still possible 
that some EV contamination could occur following this step.  
Another challenge with EV experiments is small amounts of sample volume. Isolation from cell 
culture media in particular is known to be challenging as vesicle concentrations are already 
dilute (101). This is further limited by the amount of sample that can be added into the SEC 
columns. A maximum of 10 mL of sample can be added to Izon qEV70 columns for any one 
isolation. Therefore, in order to isolate higher concentrations of EVs, such as that required for 
this study, increased time and labour requirements need to be taken into account. 
Alternatively, cell culture media can be ultracentrifuged in order to pellet EVs in a smaller 
volume prior to filtering through SEC columns. However, this step can cause deformation of 
the vesicles and was therefore avoided in this study (89). 
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Another constraint with isolating EVs from cell culture media is that there is a limit to the 
amount of media that can be collected. As these were primary cells, media collections were 
limited by the amount of cells over the course of culturing, as well as the size of the culture 
flasks themselves. Additionally, cells are known to show some functional differences as they 
progress in vitro, therefore isolation from a single passage may not be representative of cell-
states in other passages (102). It was therefore decided that all culture media used to isolate 
EVs would be collected from passages two and three to ensure the most consistency in cells. 
This further limited the amount of cell culture media that was able to be obtained, limiting the 
overall volume of isolated EVs. There are some cell culture systems that partially overcome 
some of these challenges. In particular, Hollow Fibre Bioreactors have been developed to 
combat these limitations (103). These flasks allow for long term culturing of cells through 
continuous replacement of media, as well as removal of waste products. Products secreted by 
cultured cells, such as EVs, are also collected and concentrated by the system. This allows for 
highly concentrated harvesting of EVs, which overcomes the limitation of low media volumes 
that occurs when using traditional cell culture flasks (103). As this was a pilot study, traditional 
cell culture flasks were used in order to develop techniques for examining ADSC-EV function 
and the amount was sufficient for all in vitro work. In future, for the investigation of ADSC-EVs 
as a therapeutic intervention, bioreactor flasks should be considered to reduce the need for 
large volumes of culture media, as well as minimising EV isolation time. 
A well-known limitation of EV experiments is the inability to ensure 100% purity of EV isolation 
(104). This is an aspect of EV studies that needs to be considered, as there are likely to be 
small amounts of contaminating protein aggregates, cellular debris, or lipoproteins of a similar 
size regardless of the isolation technique (104). The use of SEC columns, coupled with the 
decision to exclude the fifth fraction allowed this study to produce samples with the highest 
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possible purity of EVs in order to overcome this limitation as best as possible. Presence of 
abundant contaminating lipoproteins, such as LDL or HDL, using Western blot or Cobas 
analysis, could be assessed to determine the proportion of lipoprotein contaminants present 
in the fractions. These techniques are available in our laboratory and would confirm the purity 
of our current EV isolation techniques. 
 
4.4.6 Conclusions 
The combination of TRPS characterisation and Western blot analysis allows us to confirm that 
the particles isolated from ADSC cell culture media were EVs. In future, it would be useful to 
run isolated EV samples through a range of nanopores in order to attempt to characterise a 
wider range of EVs that could be more representative of the sample as a whole. This would 
take into account some of the limitations of these techniques and allow for better 
characterisation of the particles isolated from the patient samples. 
EVs have been proven to be a promising potential therapeutic agent due to their ability to 
transfer information between cells. ADSC-EVs in particular have been shown to promote anti-
inflammatory properties, such as stimulating signalling pathways involved in wound healing, 
promoting angiogenesis, and enhancing overall tissue repair. These potential anti-
inflammatory properties of ADSC-EVs could be targeted in fat grafting in order to minimise 
tissue reabsorption by creating an anti-inflammatory microenvironment. In order to target 
ADSC-EVs for therapeutic use, methods need to be developed to successfully isolate and 
characterise them. This study established methodologies to isolate EVs from cultured human 
ADSCs, as well as characterisation of the isolated particles. These methodologies can be used 




4.5 Polarized Macrophages Look Morphologically Different and 
Express Different Markers 
Macrophages were used in this study as they are considered an important cell in graft 
retention due to their role in inflammation. M2-like macrophages have been shown to 
increase angiogenesis, stem cell recruitment, and overall graft retention in animal studies, 
proving that macrophage polarization could play an important role in graft retention (59). 
Macrophages can be stimulated in vitro to take on a phenotype (M0, M1, or M2), which are 
deemed unpolarized, pro-inflammatory, or anti-inflammatory respectively (105). While M1 
and M2 cells are generally considered as two distinct cell types, it has been proven that 
macrophage polarization is a continuum as opposed to distinct phenotypes in vivo (105). Cells 
with M1-like characteristics are involved in stimulating the immune response, while M2-like 
cells are important for dampening this response in order to promote tissue repair (57, 58). 
Each of these cell types are morphologically different, and are induced in vitro by different 
pro- and anti-inflammatory cytokines in order to induce a response (105). The balance of these 
polarization states is vital in both the body’s response to pathogens or infection, as well as the 
preservation of host tissue (57, 58). 
In fat grafting, the main caveat is the variability in the amount of tissue retained. Currently, 
30-70% of the grafted tissue is retained, indicating that a large proportion is reabsorbed (25). 
Inflammatory cells, such as macrophages, are likely an important regulator of this process as 
they have the ability to both stimulate and regulate the immune response (57, 58). This study 
therefore investigated the potential shift in the polarization of M0, M1-like, and M2-like 
macrophages in response to ADSC-EVs. Prior to being able to investigate this relationship, we 
needed to establish methodologies for in vitro polarization of macrophages. 
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Macrophages were polarized towards M1-like, M2-like, or M0 while in cell culture and 
polarization was assessed morphologically, by flow cytometry, and using RT-qPCR. Each of the 
three polarization states looked morphologically different, and also expressed differing levels 
of confirmatory markers used across both the flow cytometry and RT-qPCR methodologies. 
One of the most significant challenges with polarizing macrophages is that polarization is a 
spectrum, and therefore it is difficult to classify cells as M1 or M2 (55). This can introduce 
challenges with the methods used to classify polarization states. In this study, we examined 
the expression of pro- and anti-inflammatory markers known to be associated with M1 and 
M2 polarizations by RT-qPCR, as well as the presence of M1 and M2 markers by flow 
cytometry. Both of these methods indicate whether cells are portraying more M1-like or M2-
like characteristics, and it is likely that macrophages from both polarization states will be 
expressing varying levels of both M1 and M2 markers. Thus, morphology, flow cytometry, and 
RT-qPCR were examined to clarify how well the polarization employed works. 
 
4.5.1 Polarized Macrophages Look Morphologically Different 
Morphological appearances of these three polarization states are well established, and all of 
these cell types look as expected, indicating successful polarization (106). Macrophages 
polarized to M1, had a rounded appearance, while macrophages polarized to M2 appeared 
stretched and spindly. M0 macrophages have a mixture of these two morphologies. Therefore, 




4.5.1.1 Suitability of Polarizing Agents 
In our study, GM-CSF and IFN-γ were used to stimulate M1 polarization, and M-CSF and IL-4 
for M2 polarization. The doses and stimulants used are common inducers of polarization in 
cell culture experiments (54, 107, 108). In humans, GM-CSF and M-CSF are haematopoietic 
growth factors that have roles in activation, differentiation, and survival of M1 and M2 
macrophages respectively (109). The polarization properties of these cytokines have been 
proven to be well translated to cell culture experiments, demonstrating their ability to induce 
polarization of macrophages (54, 107). It has been proven that the addition of other cytokines, 
such as IFN-γ and IL-4, can further polarize macrophages to M1 and M2 (110, 111). IFN-γ is 
involved in stimulating macrophages to produce more pro-inflammatory cytokines, and less 
anti-inflammatory cytokines (110, 111). It is therefore involved in polarizing macrophages to 
M1, and suppressing the polarization towards M2 (110, 111). IL-4 is also a widely used 
stimulant for M2 polarization (54). IL-4 is important in supressing production of pro-
inflammatory cytokines, and therefore is a strong stimulant for M2 polarization (112). 
Aside from the stimulants used here, there are a wide range of other stimulants that have 
been proven to polarize macrophages towards a more M1-like or M2-like phenotype. 
Alongside IFN-γ, lipopolysaccharides and IL-6 have both been proven to be strong stimulants 
for M1 polarization (54). Additionally, IL-13 and IL-6 have both been proven to aid in M2 
polarization (54). It has also been proven that phasing the addition of different polarization 
stimulants can increase the level of polarization (54). Culturing in GM-CSF or M-CSF for five 
days first, followed by culturing cells in a cocktail of each of the above stimulants for a further 
four days, results in increased segregation of M1 and M2-like cells (54). While this is not as 
common as the polarization technique we used, it could be explored in order to establish a 
better picture of how well the polarization used here works. However, macrophage cultures 
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look as expected for each of the polarization states, indicating successful polarization towards 
M1 and M2 macrophages.  
 
4.5.2 Polarized Macrophages Express Different Levels of M1 and M2 Markers 
Flow cytometry was also performed to assess polarization states using known M1 and M2 
markers. The marker expression using flow cytometry did not clearly identify M1 or M2 cells 
as expected. M1-polarized cells did not express the M1 markers, however, they also did not 
express the M2 markers. Whereas, M2-polarized macrophages expressed both the M1 and 
M2 markers. While each culture did not necessarily express M1 and M2 markers as expected, 
each population expressed these markers to different degrees, indicating that each culture is 
distinctly different.  
A significant proportion of time was spent optimizing macrophage cell counts in order to have 
a sufficient number of cells to complete flow cytometry. Initially, macrophages were isolated 
from 10 mL of whole blood, however, the amount of cells obtained from this isolation proved 
to be insufficient for flow cytometry analysis. Optimization experiments involved isolation of 
macrophages from 10 mL, 15 mL, and 20 mL of blood in an attempt to isolate increased 
numbers of macrophages. Isolation from 20 mL was sufficient to complete some preliminary 
flow cytometry analysis, however, an increased cell count would be optimal for future 
experiments. Due to this, flow cytometry analysis was only completed on macrophages from 
one healthy volunteer, which is one potential reason for the unexpected flow cytometry 
analysis results. Therefore, further optimisation would need to be completed to optimise cell 
counts in order to further assess the putative M1 and M2 markers used in this panel. 
There is also currently a lack of consensus in the literature for defining M1 and M2 populations 
using flow cytometry. The panel for assessing M1 and M2 polarization was therefore designed 
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using a selection of papers that stimulated macrophages in a similar manner (54, 113-117). 
There are a number of other markers, and combinations of markers, that could be trialled to 
characterize these cell types. From the preliminary data, the chosen putative M2 markers 
demonstrate the potential to characterise M2-like populations, as they were highly expressed 
on the small population of cells analysed. An increased cell count, coupled with an increased 
sample size, could therefore further assess the potential of these markers. However, due to 
M1 cells not expressing any of the putative markers, the assessment of other potential M1 
markers is likely necessary. While the sample size was small, M1 markers were not expressed 
on any of the M1-polarized population, indicating the need to reassess these markers in 
conjunction with optimizing overall cell counts and sample size. 
It should also be noted that these macrophage populations were only polarized for 48 hours, 
as opposed to the seven-day polarization for RT-qPCR, due to availability of equipment and 
time constraints. Polarization for 48 hours is commonly used to initiate polarization, however, 
as polarization is a spectrum, and not distinct phenotypes, it is therefore possible that the 
markers used for flow cytometry analysis require longer periods of stimulation before they 
are highly expressed. Polarization for seven days could have allowed for increased 
differentiation between the two states, and thus potentially increased expression of each of 
the respective markers. Additionally, due to the short polarization period, it is likely that the 
cultured cells are a heterogeneous population of M0-like, M1-like and M2-like cells. 
 
4.5.3 Polarized Macrophages Express Different Levels of Inflammatory Markers 
To further assess the polarization states, macrophages were lysed and expression of pro- 
(TNFα, IL-1β) and anti-inflammatory (IL-10, TGFβ) markers were analysed using RT-qPCR. 
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However, low cell counts and sample size made it difficult to conclude polarization states from 
RT-qPCR alone. 
 
4.5.3.1 Suitability of the Markers 
TNFα is well-established as a potent pro-inflammatory mediator and is secreted by M1 
macrophages (118). This cytokine is involved in a diverse range of pro-inflammatory signalling 
pathways, ultimately leading to enhanced inflammation, necrosis, and apoptosis of foreign 
substances (118). TNFα has also been found to enhance the production of GM-CSF, indicating 
an involvement in driving macrophage polarization towards a pro-inflammatory state (119). 
The increased expression of TNFα in M1 macrophages compared to M0 and M2 was therefore 
as expected. 
IL-1β is another potent pro-inflammatory mediator involved in the host response to pathogens 
(120). M1 macrophages are the primary producers of IL-1β, releasing it in significant amounts 
in response to stimulation from GM-CSF during inflammation (120). IL-1β is therefore a marker 
to assess M1 polarization. While M1 macrophages are known to upregulate IL-1β expression 
in vivo, there are currently mixed results as to its upregulation in cell culture alone (121). It 
has been concluded, that in cell culture experiments, TNFα is a more reliable measure of M1 
polarization than IL-1β (121). 
In this study, TNFα demonstrated successful polarization, as M1 macrophages expressed 
significantly more TNFα mRNA than M0, while M2 macrophages expressed similar levels to 
M0 macrophages. IL-1β expression decreased in M1 macrophages relative to M0, however, 




IL-10 is a well-established cytokine released by M2 macrophages that is known to resolve 
inflammation in order to prevent tissue damage to the host, and was hypothesised here as a 
suitable marker for assessing M2 polarization (122). However, no change in the expression of 
IL-10 was detected between the polarization states.  
TGFβ is another important regulatory cytokine involved in suppressing the immune response 
in order to control inflammation, particularly in response to wound healing (123). TGFβ 
directly impacts almost all immune cells in order to regulate proliferation, differentiation, and 
cytokine release (123). It is known to promote M2 polarization, while also suppressing pro-
inflammatory properties, such as those of M1 macrophages (56, 123). In this study, TGFβ 
expression was unexpectedly increased in both M1 and M2 macrophages. 
The expression of IL-10 and TGFβ were unexpected, as they did not correlate to the successful 
polarization analysed by cell morphology, and this is likely due to the small sample size. As 
outlined earlier, the cell counts for the three healthy volunteers were not sufficient to carry 
out flow cytometry analysis and were therefore pooled before analysis. These pooled samples 
were also analysed using RT-qPCR. It is likely that the pooled samples, resulting in the overall 
analysis of one single sample, could be masking the effect of these markers. These markers 
are all potent pro- and anti-inflammatory mediators, and have been previously proven to be 
promising markers of macrophage polarization, which is why they were selected for this study. 
Further optimization of cell counts would remove the need to pool samples and therefore an 
increased sample size could be analysed in order to determine whether these markers are a 





Polarization is a spectrum, with cells being stimulated towards displaying more M1-like or M2-
like characteristics. Macrophage polarization could be confirmed with visualization, however, 
it is more difficult to conclude by flow cytometry and RT-qPCR, but this may be due to low 
cells counts and the subsequent need to pool samples. Aside from morphology, we need to 
optimize our methodologies for identifying these different polarization states. This model 
therefore showed that it is possible to polarize macrophages towards M1 or M2, however 
further investigation into the markers and the optimal way to initiate polarization should be 
completed. 
 
4.6 ADSC-EVs Potentially Impact Macrophage Markers 
The expression of pro- (TNFα, IL-1β) and anti-inflammatory (IL-10, TGFβ) markers was 
analysed using RT-qPCR for each of the polarization states both with and without the addition 
of ADSC-EVs. There were varied expressions of all of the markers with the addition of ADSC-
EVs, with the most marked increase in IL-1β, particularly for M2 macrophages. IL-10 and TNFα 
increased in M0 macrophages following the addition of EVs, but did not change for M1 and 
M2. TBGβ expression decreased in M1 and M2 macrophages following the addition of EVs, 
but not for M0.  ADSC-EVs therefore appear to have an effect on the expression of these 
markers, although it is difficult to conclude exactly what these changes are. 
At the initial chosen dose of 2x109 cells/mL, cells treated with ADSC-EVs had lower cell counts 
than cells that had not been treated, indicating cell death was possibly occurring, however, 
this was not directly measured. This is unexpected, as ADSC-EVs have previously been found 
to exhibit anti-inflammatory properties, as well as reduced levels of necrosis, in mouse fat 
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grafting models (36). It is therefore possible that the dose of ADSC-EVs administered was toxic 
for the number of macrophages per culture. This dose was used in this preliminary study in 
order to ensure that a response could be elicited. Further optimisation, including a dose-
response curve and cell death assays, should therefore be included in future research in order 
to determine if ADSC-EVs are in fact causing cell death. 
Additionally, macrophages from the three healthy volunteers had to be pooled in order to 
have a sufficient number of cell counts to perform analysis. It should also be noted that this 
experiment was only completed using EVs isolated from one patient, as this was the only 
patient that had a sufficient amount of cell culture media following optimisation. Following 
further optimisation, an increased sample size would be required to determine the impact of 
ADSC-EVs on macrophage polarization. 
Initially, we planned to analyse macrophage polarization with and without ADEC-EVs using 
flow cytometry on the same M1 and M2 markers as outlined earlier. There were a number of 
factors that limited us to RT-qPCR alone. As described earlier, there were difficulties obtaining 
sufficient cell counts to perform flow cytometry on macrophages without ADSC-EVs. The 
addition of ADSC-EVs resulted in a significant decrease in cells, further reducing cell count. 
Even following the pooling of samples, there was an insufficient number of cells to complete 
flow cytometry analysis. Further optimisation of macrophage isolation, coupled with dose 
response experiments, should allow for optimised cell counts to perform flow cytometry 
analysis. The use of both flow cytometry and RT-qPCR together will allow for further 
understanding of the role of ADSC-EVs on macrophage polarization. 
We are therefore limited in our ability to draw a conclusion regarding the pro- or anti-
inflammatory properties of ADSC-EVs on macrophages. Further studies would need to be 
conducted in order to better understand whether ADSC-EVs promote M2-like characteristics. 
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4.7 Future Directions 
This study is part of a larger ongoing study that is assessing graft retention using Magnetic 
Resonance Imaging (MRI). Using the same patient cohort, this larger study is comparing tissue 
weights retained in the breast through the use of pre- and post-surgery MRIs. The results of 
our study could help to determine which aspects of the graft may influence retention. ADSC 
and ADSC-EV counts could both be used comparatively with the MRI data to determine if there 
is a correlation between retention and levels of these cells or EVs. Furthermore, if a 
relationship is found, this could influence how we enrich ADSCs or ADSC-EVs in the future to 
promote graft retention. 
This results obtained from this study have provided the foundations for a wide range of 
possible future studies on the role of ADSC-EVs. Firstly, as described earlier, a dose response 
relationship should be investigated in order to obtain the optimal dose of ADSC-EVs to elicit a 
response while also minimising cell death. The results from this study indicate that the dose 
administered here may be inducing cell death, and in order to investigate this further a dose-
response relationship should be investigated. 
Additionally, in order to further understand the role of ADSC-EVs on macrophage polarization 
it would be advantageous to complete flow cytometry alongside RT-qPCR analysis, as 
originally planned. In order for this to take place, further optimisation into cell counts of 
isolated macrophages would need to be investigated. Additionally, reassessment of the 
M1/M2 flow cytometry panel would need to be considered to develop a panel that is more 
representative of the polarization states. 
Following further optimisation of the above, it would be beneficial to also increase the sample 
size. Due to difficulties obtaining large enough cell counts, this study had to pool macrophage 
populations from three healthy volunteers. Additionally, due to time constraints and clinical 
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timelines, only ADSC-EVs from one patient were applied to macrophage cultures. While this 
allowed for the development of these preliminary results, increasing the sample size will allow 
for a further understanding of the impact of ADSC-EVs on macrophage polarization. 
Furthermore, the co-culturing of ADSCs and macrophages could also be investigated to 
elucidate whether the ADSC effects are due to EVs alone, or if other cellular factors are also 
important. The comparison of this technique with the current co-culturing of macrophages 
and EVs, would help to determine which aspects of ADSCs are most important in this 
relationship. This would allow for the clinical enrichment of ADSCs to be tailored in order to 
exploit the signalling mechanisms that are most likely to provide optimal graft retention. 
Once the role of macrophages has been further investigated it would also be advantageous to 
investigate other stromal cells. Macrophages are not the only cell present in the breast cavity 
that could be important in facilitating the relationship with ADSCs. The techniques developed 
in this study can be translated to experiments investigating other prevalent cell types, such as 
fibroblasts and adipocytes, in order to develop a wider understanding of the signalling 
processes involved in overall graft retention. 
 
4.8 Clinical Implications 
Breast cancer is the most commonly diagnosed cancer among women both in New Zealand 
and worldwide. However, the approximate 5-year survival rate following treatment, which 
usually consists of surgical removal of the breast, is 90%. Therefore, a large proportion of 
women are having breast reconstruction surgery, and there is a need for improved 
reconstruction options.  
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We hypothesised that the application of ADSC-EVs to macrophages would promote M2-like 
characteristics, indicating an overall anti-inflammatory response. However, on the basis of the 
results of this study alone, we are limited in our ability to draw any conclusions regarding their 
pro- or anti-inflammatory properties. 
If ADSC-EVs prove to promote an anti-inflammatory response, the enrichment of ADSCs could 
aid in minimising tissue resorption, leading to improved overall graft retention. This could help 
to provide a safer, more equitable breast reconstruction option to women.  
Furthermore, increased knowledge about the inflammatory properties of ADSC-EVs could help 
us to manipulate them to promote anti-inflammatory properties. Further investigation could 
allow for the development of a cell culture model that could, in future, be translated into the 
clinical setting. This model could help to determine a way to isolate and enrich liposuctioned 
ADSC-EVs to develop anti-inflammatory properties, before being reinjected into the breast 
cavity. 
As some of our results are conflicting, there is also the potential that ADSC-EVs could promote 
inflammation. There are currently clinicians already enriching ADSCs prior to inserting them 
back into patients, with the hope that this will improve graft retention. While there is some 
evidence supporting their anti-inflammatory properties in animal studies, there is little 
evidence as to if this can be translated to humans. It is therefore important to be informed if 
they are found to promote inflammation, as it may be detrimental to enrich these cells if they 





There is an apparent need for a safe, equitable breast reconstruction option in order to 
improve the physical, physiological, and social aspects of the everyday lives of women 
impacted by breast cancer.  
The overall aim of this pilot study was to determine the impact of ADSC-EVs on macrophage 
polarization, and on the expression of pro- and anti-inflammatory markers. Our data shows 
that it is possible to isolate viable ADSCs and the subsequent released EVs, from patients 
undergoing fat grafting treatment. We demonstrate the ability to characterise the isolated 
EVs, as well as isolate and polarize macrophages in vitro. We also demonstrate that ADSC-EVs 
appear to have an impact on the expression of pro- and anti-inflammatory markers in 
polarized macrophages. While it cannot yet be determined whether ADSC-EVs promote M2-
like polarization of macrophages as hypothesised, the foundations developed from this study 
provide an exciting platform for future research into the potential role of ADSC-EVs in tissue 
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Appendix 1: Participant Information Sheet and Consent Form 
 
 
Participant Information Sheet 





Department of Surgery & Anaesthesia, 
University of Otago Wellington 
Contact phone 
number: 
(04) 918 5049 
 
Introduction 
You are invited to take part in a study examining samples from healthy controls as a baseline 
measure of molecular inflammatory processes. Whether or not you take part is your choice. If 
you don’t want to take part, you don’t have to give a reason. If you do want to take part now, 
but change your mind later, you can pull out of the study at any time.  
This Participant Information Sheet will help you decide if you’d like to take part.  It sets out why 
we are doing the study, what your participation would involve, what the benefits and risks to 
you might be, and what would happen after the study ends. We will go through this information 
with you and answer any questions you may have. You do not have to decide today whether 
or not you will participate in this study. Before you decide, you may want to talk about the study 
with other people, such as family, whānau, friends, or healthcare providers.  Feel free to do 
this. 
If you agree to take part in this study, you will be asked to sign the Consent Form on the last 
page of this document. You will be given a copy of both the Participant Information Sheet and 
the Consent Form to keep. 
This document is 5 pages long, including the Consent Form. Please make sure you have read 




What is the purpose of this study? 
This study is looking at measures of molecular and inflammatory markers in healthy individuals. 
This is to determine baseline measures of markers that can then inform studies related to 
molecular inflammatory processes including but not limited to cancer and cardiovascular 
disease. 
Who are we seeking to be involved in the project? 
We are asking you to be involved in this project because you have self-reported as being 
healthy with no significant medical problems. 
If you participate, what will you be asked to do? 
You will be asked to undergo a blood draw and answer a few simple questions about your age, 
ethnicity, and medical history.  
What data or information will be collected, and how will it be used?  
We will verbally collect some demographic data from you (such as your age, sex and ethnicity) 
and some information on your medical history (e.g. if you have ever been hospitalised or 
diagnosed with a condition such as heart disease). We can link this information to any findings 
from testing your blood sample. However, your confidentiality is extremely important to us, and 
all your information will be stored on a secure password protected database. With your 
permission we would like to have the opportunity to contact you in the future regarding your 
sample, in case we have any further questions. We can also provide information that arises 
from future research to you, if you are interested.  
What happens to my samples after they have been collected? 
Once the samples have been collected they will be taken to a secure laboratory where they 
will either be frozen prior to undergoing testing or be isolated for cell culture. The types of lab 
tests that we will do on the samples may include measuring inflammatory markers, isolating 
DNA or RNA, or examining signalling molecules that are released from cells. 
Samples will be kept only for the duration of this study, which is up to 5 years. At the conclusion 
of the study all samples will be disposed of in a biohazard bin which will then be incinerated. 
We recognize cultural issues may arise for Māori and Pacific populations with the donation of 
tissue. We are able to offer an alternative disposal method, where samples will be disposed of 
with an appropriate karakia, approved by the Kaitakawaenga Rangahau Māori at the University 
of Otago. 
What are my rights? 
Donating samples for this research is entirely voluntary and you are free to decline 
participation. You will not own any intellectual property that may arise from research using 
your samples. If you do participate and change your mind at any time, you are able to 
withdraw consent by using the contact information below. You will not be compensated for 






If you have any questions now or in the future, please feel free to contact: 
Name Kirsty Danielson 
Position Lecturer 
Department Surgery & Anaesthesia, University 
of Otago Wellington 
Contact phone number: 
(04) 918 5049 
kirsty.danielson@otago.ac.nz 
 
For Māori health support please contact : 
Whānau Care Services 
(04) 806 0948 
wcs@ccdhb.org.nz 
If you want to talk to someone who isn’t involved with the study, you can contact an 
independent health and disability advocate on: 
Phone:  0800 555 050 
Fax:   0800 2 SUPPORT (0800 2787 7678)  
Email:   advocacy@hdc.org.nz 
 
You can also contact the health and disability ethics committee (HDEC) that approved 
this study on: 
Phone:  0800 4 ETHICS 
Email:  hdecs@moh.govt.nz 





















Healthy controls as a baseline measure of molecular 
inflammatory processes 
 Principal Investigator: Dr Kirsty Danielson (kirsty.danielson@otago.ac.nz, (04) 918 5049) 
CONSENT FORM FOR PARTICIPANTS 
Following signature and return to the research team this form will be stored in a secure place 
for five years. 
1. I have read, or have had read to me in my first language, and I understand the 
Participant Information Sheet. 
2. I have had sufficient time to talk with other people of my choice about participating 
in the study and to consider whether or not I would like to take part.   
3. I am satisfied with the answers that I have been given regarding the study and I 
have a copy of this consent form and the information sheet.  
4. I understand that taking part in this study is voluntary (my choice). 
5. I consent to the research staff collecting and processing my verbally provided 
information  
6. I would like any remaining samples to be disposed of at the end of the study 
(please tick one) 
o Using standard disposal methods 
o Disposed with appropriate karakia 
7. I understand that I may withdraw from the study at any time. 
8. If I withdraw from the study, I agree that the information collected about me up to 
the point when I withdraw may continue to be used. 
9. I know whom to contact if I have any questions about the study in general.  











Declaration by participant: 




Signature of participant: 
  
Date: 
   
   
Declaration by member of research team: 
I have given a verbal explanation of the research project to the participant, and have 
answered the participant’s questions about it. 





Researcher’s signature:  Date: 






Appendix 2: ADSC Flow Cytometry for AD10 
 
Figure S1: Gating strategy to identify live ADSC population. 
ADSCs were identified by their forward scatter (FSC-A) and side scatter (SSC-A) properties (A). Doublet exclusion 
was performed by examining the FSH-H vs. FSC-A profile (B) and, finally, live cells were gated on based on their 




Figure S2: ADSCs are negative for the expression of the monocyte marker, CD14, and the endothelial marker, 
CD31. 
ADSC populations were negative for the expression of CD14 and CD31 (A & C). PBMCs had positive expression of 





Figure S3: ADSCs are positive for the expression CD105 and CD10. 
A) CD105 FMO showed no positivity of CD105, but 99.1% expression of CD10 on the ADSC population. C) CD10 
FMO showed no positivity of CD10, but 99.5% positivity of CD105. B) Full stain showing 99.2% of cells expressing 





Figure S4: ADSCs are positive for the expression CD105 and CD166. 
A) CD105 FMO showed no positivity of CD105, but 99.1% expression of CD166 on the ADSC population. C) CD10 
FMO showed no positivity of CD166, but 98.3% positivity of CD105. B) Full stain showing 99.4% of cells expressing 





Appendix 3: EV Characterisation Histograms 
 
Figure S5: Concentration versus particle diameter histograms of particles measured using TRPS 
Particles were isolated using SEC columns from ADSC cell culture media and the first four pooled fractions were 
characterised using TRPS on the qNano Gold. Concentration (particles/mL) and particle diameter (nm) were 
measured and graphed against one another. Each histogram represents an individual patient; A) AD5, B) AD7, C) 
AD8, D) AD10, E) AD12. All samples demonstrated a normal distribution. Samples measured on an NP200 
nanopore applying a stretch ranging from 46.9-47.1 mm. Voltages used were between 0.32 and 0.36 V, and 




Appendix 4: Antibody Titration for Macrophage Flow Cytometry 
 
Figure S6: Antibody titration for putative M1 and M2 markers using M0 macrophages. 
Macrophages were cultured at M0 for one week and expression of putative M1 (CD80, CD68, CD86) and M2 (CD163, CD206, CD36) markers were analysed by flow cytometry. 
Titrations included neat (manufacturers recommendation; blue), 1:4 (green), 1:8 (pink), and an unstained control (red). M0 macrophages did not express putative M1 markers (A-
C). M0 macrophages expressed all putative M2 markers (D-F), with increased expression as antibody concentration increased. 
